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APC antigen presenting cell MV mature virion 
ARE AU-rich element MVA modified vaccinia virus Ankara 
B-LCL 
CEF 
B lymphoblastoid cell line 
chicken embryo fibroblasts 
NCBI National Center for Biotechnology 
Information 
CID collision-induced decomposition NIC nicotinic acid 
CLIP class II-associated invariant chain peptide NK natural killer 
CPXV cowpoxviurs ORF open reading frame 
CTL cytotoxic T cell p.b. post boost 
CVA chorioallantois vaccinia virus Ankara PAGE polyacrylamide gel electrophoresis 
D4NIC deuterated NIC PBMC peripheral blood mononuclear cell 
DC dendritic cell PBS phosphate-buffered saline 
DMSO dimethylsulfoxide pDC plasmacytoid DC 
DNA deoxyribonucleic acid PE phycoerythrin 
ds double-stranded pep peptide 
EBV Epstein Barr virus PFU plaque forming unit 
ECTV ectromelia virus PMA phorbol myristate acetate 
EDTA ethylenediaminetetraacetic acid PRR pattern recognition receptor 
EEV extracellular enveloped virion pS phosphoserine 
ELISPOT enzyme linked immunosorbent spot pT phosphothreonine 
ER endoplasmic reticulum Q-TOF quadrupole-time of flight 
ESI electrospray ionization RCC renal cell carcinoma 
FACS fluorescent-activated cell sorting RNA ribonucleic acid 
FCS fetal calf serum s.c. subcutaneous 
FITC fluorescein-5-isothiocyanate SCX cation exchange chromatography 
Gua guanylated SDS sodium dodecyl sulfate 
H4NIC hydrogenated NIC SEM standard error of the mean 
HCMV 
HIV 
human cytomegalovirus 
human immunodeficiency virus 
SEREX serological identification of antigens 
by recombinant expression cloning  
HLA human leukocyte antigen SFC spot forming cells 
HPLC high performance liquid chromatography SITE stable isotope tagging of epitopes 
i.m. intramuscular ss single-stranded 
IFN 
Ig 
interferon 
immunoglobulin 
stim. 
TAA 
stimulation 
tumor-associated antigen 
IL 
IMAC 
interleukin 
immobilized metal affinity chromatography 
TAP transporter associated with antigen 
processing 
IMV intracellular mature virion TCR T cell receptor 
IU international unit TH T helper 
LC-MS/MS HPLC-coupled tandem MS analysis TiO2 titanium dioxide 
m/z mass to charge ratio TLR Toll-like receptor 
mDC myeloid DC VACV vaccinia virus 
MHC major histocompatibility complex VARV variola virus 
MOAC metal oxide affinity chromatography WHO World Health Organisation 
MOCV molluscum contagiosum virus WR Western Reserve 
MPXV monkeypoxvirus wt wild type 
MS mass spectrometry y year 
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1 General introduction 
1.1 The sixth sense - immune receptors 
A diversity of cellular sensors have evolved in order to discriminate between self, 
altered self (tumors) and non-self (viruses, bacteria and eukaryotic parasites) in or 
around mammalian cells. Basically, there are two types of defense mechanisms, which 
differ in the receptors used to recognize pathogens: innate and adaptive (also known as 
acquired).  
Innate immune recognition is mediated by germline encoded pattern-recognition 
receptors (PRR), which are characterized by broad specificities for conserved and 
invariant features of microorganisms (1, 2). PRR engagement leads to host 
inflammatory, anti-pathogen and cell death effector mechanisms mediated by  
macrophages, neutrophils, natural killer cells (NK cells), and the complement system. 
This provides a first line of defense, which optimally controls an infection in the first 
four days before an initial adaptive immune response takes place. 
Adaptive immune recognition is mediated by antigen-specific receptors. The genes 
encoding these receptors are assembled from gene segments in the germ line, and 
somatic recombination of these segments yields a diverse repertoire of receptors with 
random but narrow specificities (3). This diversity is further increased by additional 
mechanisms, such as non-templated nucleotide addition, gene conversion and (in the 
case of B cells) somatic hypermutation, generating a highly diverse repertoire of 
receptors with the potential to recognize almost any antigenic determinant in a 
specific manner. These specific antigen receptors are clonally distributed on T and B 
lymphocytes, which allows clonal selection of pathogen-specific receptors and is the 
basis for immunological memory. Since, in a non-immune individual, only an 
extremely small fraction of the adaptive immune cell repertoire (e.g., one in a million) 
will have an antigen receptor capable of recognizing a specific antigen, clonal 
amplification of these specifc cells takes days to evolve. T-helper (TH) cells marked by 
the co-receptor CD4 on the cell surface and cytotoxic T cells (CTL) expressing CD8 
recognize antigenic peptides bound to major histocompatibility complex (MHC) class 
II and class I molecules (also called human leukocyte antigens, HLA), respectively. 
They are the cells of the so-called cellular immunity. As the term HLA indicates, these 
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molecules are also involved in rejection of transplanted non-self tissue based on the 
fact, that every person has an individual set of HLA alleles, which bind different types 
of peptides and are co-recognized by T cells. B cells can recognize almost any type of 
antigen by binding to a specific three-dimensional molecular determinant. They 
constitute humoral immunity.  
 
     
 
The innate and adaptive immune system complement each other (4) (Figure 1.1). 
Microbial antigens are taken up by professional antigen-presenting cells (APCs), such 
as dendritic cells (DCs), in the peripheral tissues and are delivered to the lymph nodes 
or spleen through the lymph or blood, respectively, where they are recognized by 
antigen-specific B and T cells. Since specificity of B and T cell antigen receptors is not 
directly linked to the origin of the antigen, the differentiation of lymphocytes into a 
particular effector-cell type and their localization to the site of infection are regulated 
by the instructions provided by the innate immune system, generally in the form of 
cytokines and chemokines, respectively: for specific T cell activation, and in the case 
of TH (CD4+) cells for differentiation into one of several types of effector TH cell (TH1, 
TH2 and TH17, characterized by different cytokine production), it is essential that PRRs 
induce DCs to produce cytokines and to express cell-surface signals; for specific B cell 
Figure 1.1 Recognition of pathogens
and activation of the immune 
response (1). Pathogens induce a
fast innate immune response through 
PRRs, which activates the 
appropriate set of cells of the 
antigen-specifc adaptive immune 
response. An adaptive immune 
response results in boosting of the 
same innate immune response that 
instructed the adaptive immune 
response. 
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activation against so called T-dependent antigens (mostly proteins) effector TH cells, 
which have previously been activated by DCs, are necessary. 
In addition to the conventional T and B cells, there are lymphocytes with innate-like 
characteristics. The innate-like B-1 cells reside in the peritoneal and pleural cavities 
and produce mainly antibodies of the IgM class against some common bacterial 
polysaccharides and some self antigens (5). Innate-like T cells recognize the non-
classical MHC molecules class Ib molecules, which present bacteria-specific ligands, 
for example, bacterial lipids or formylated peptides in the case of the CD1 and H-2M3 
families, respectively. In a way, these MHC-like molecules function as PRRs, 
presenting microbial ligands to specialized T cells (6). Some non-classical MHC 
molecules might themselves be ligands for T cell receptors, without presenting any 
other molecules. In this case, the expression of these molecules is thought to be 
inducible by the engagement of PRRs on specific cell types, such as mucosal epithelial 
cells (7). 
1.1.1 Vaccination 
Prophylactic vaccines aim to generate an effective, specific and long-lasting cellular 
and humoral immunological memory against infectious agents for protection against 
future infection and disease caused by the pathogen. There are three basic types of 
prophylactic vaccines: live attenuated vaccines, inactivated whole cell vaccines and 
subunit vaccines. Live attenuated vaccines are made from weakened, or attenuated, 
viruses or bacteria that are designed to mimic some of the early stages of infection 
without causing disease. Inactivated whole cell vaccines are made by growing the 
infectious organism in culture media or mammalian cells and then inactivating the 
organisms. Subunit vaccines are derived from individual antigens that can be purified. 
Although several serious pathogens have been successfully fought by vaccination yet, 
for example smallpox virus (see chapter 1.2.2) or poliomyelitis virus 
(www.polioeradication.org), there are numerous pathogens which remain a great 
challenge for the human organism.  
Therapeutic vaccines aim to strengthen or modify the immune response in patients 
already suffering from the disease. Great effort is being devoted to developing 
therapeutic vaccines against tumors, AIDS, hepatitis B, tuberculosis, malaria, and 
autoimmune diseases (8). The vaccination-based induction of a specific anti-tumor 
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immune response bears the potential to reject malignant cells or at least to support 
current therapies in a highly specific manner.  
1.1.2 T cell induction by MHC class I and II antigen presentation 
Adaptive cellular immunity by T cells is mediated by binding of the specific T cell 
receptor (TCR), which is composed out of an α- and β-chain, to MHC-peptide 
complexes (9). CD8+ T cells recognize the complex of MHC class I molecules with 
peptides of 8 to 12 amino acids derived mainly from intracellularly produced and 
degraded proteins (10). CD4+ T cells recognize peptides of 9 to 25 amino acids, which 
are mainly derived from membrane-bound proteins or from extracellular proteins 
internalized by endocytosis, on MHC class II molecules, which, physiologically, are 
exclusively expressed by APCs, e.g., DCs (11). 
Molecules of each MHC class are expressed by three genetic loci (called HLA-A, -B, 
and -C for human class I and HLA-DR, -DQ and -DP for human class II) that encode 
structurally similar but non-identical proteins. Each of these loci shows a tremendous 
genetic polymorphism, with hundreds of different allelic forms having been defined 
(www.anthonynolan.com/HIG). This creates a very large genetic pool of structurally 
distinct HLA class I and II, from which a small subset (six alleles each) are represented 
in any individual human being. Most of the polymorphic differences among MHC 
molecules encoded by different genes and alleles alter the structure and specificity of 
the peptide-binding groove. Hence, the MHC polymorphism results in an increase in 
the overall information content displayed population-wide on cells for inspection by 
the immune system. Any of the HLA-A, -B, and -C alleles  binds a repertoire of 
peptides, which share an amino acid sequence motif corresponding to two or more 
essential amino acids, the so-called peptide anchor residues (10, 12, 13). Pockets in the 
peptide-binding groove of MHC molecules contain particular amino acids 
corresponding to the anchor residues of the peptide ligand (14-16). Most HLA class I 
require anchor residues at position 2 and at the C-terminus (www.syfpeithi.de). A B 
lymphoblastoid cell displays an estimate of 10,000 to 20,000 different peptides at 
greater than one copy by an individual class I and II MHC allelic form (12), 
representing a potential total display of 30,000 to 120,000 peptides.  
Peptide fragments binding on HLA class I are generated in the cytoplasm of any 
nucleated cell by proteasome-mediated proteolytic cleavage of cellular endogenous 
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proteins (self-HLA ligands), of viral proteins in case of infection (non-self-HLA 
ligands), and of products of self-genes that have undergone mutations (altered HLA 
ligands), e.g., during malignant transformation (17). After targeting of misfolded or 
nonfunctional proteins (18, 19) as well as of proteins designated for degradation (20) 
by ubiquitination (21, 22), they are recognized by proteasomes, which are multi-
proteinase complexes (23). In case of interferon (IFN)-γ stimulation, a cell switches 
from synthesis of the constitutive 20S core proteasome to synthesis of the 
immunoproteasome by exchange of the subunits harbouring the catalytic sites by 
immunosubunits called MECL1, LMP2 and LMP7 (24). The immunoproteasome is 
able to enhance generation of peptides presented on HLA class I (25). Proteasomes 
generate precursor HLA ligands with the final C-terminus, which are further trimmed 
by peptidases either in the cytosol (26) or in the endoplasmic reticulum (ER) (27). The 
peptides generated in the cytosplasm are transported into the ER by the transporter 
associated with antigen processing (TAP) (28). In the lumen of the ER, MHC class I 
molecules composed out of the polymorphic α-chain and the non-polymorphic β2-
microglobulin (a/β2m-heterodimers) (Figure 1.2a) are loaded with peptides (Figure 
1.2b) through interactions in the peptide-loading complex, which includes the 
transmembrane glycoprotein tapasin, the chaperone calreticulin and the thiol 
oxidoreductase ERp57 (29). Accumulated MHC class I α/β2m-peptide-complexes are 
then transported to the cell surface. 
 
           
Figure 1.2 HLA class I structure (14). a) Side view of the complex composed of the 
membrane-spanning α-chain (domains α1, α2, and α3) and the non-covalently bound β2-
microglobulin (schematic). Peptide binding occurs in the groove between domains α1 and α2. b) 
Peptide (red) bound in the peptide binding groove (top view; electron density). 
 
a              b   
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DCs can potentially initiate CTL responses through the process of direct antigen 
presentation (as just described) or through cross-presentation, which refers to the 
generation of HLA class I-peptide complexes from exogenous protein, e.g., from 
apoptotic cells (30-33). The priming of anti-pathogen or anti-tumor responses is often 
dependent on cross-priming, which is therefore an important issue in the context of 
vaccinations. The fact that, first, many viruses show strict tissue tropism and do not 
detectably infect DCs and, second, viruses often interfere with antigen presentation, 
may have contributed to the evlution of cross-priming (34). Both direct and cross-
presentation lead to cell surface expression of HLA class I-peptide-complexes along 
with costimulatory molecules, such as CD80 and/or CD86, needed to induce naïve 
CD8+ T cells. However, when a TLR ligand activates a DC, rapid maturation occurs 
and thus uptake of exogenous antigen is substantially decreased (35, 36). This finding 
is particularly critical for protein-based vaccines.  
 
 
 
Figure 1.3 Proposed pathways for cross-presentation by MHC class I molecules (37). For 
explanation see text below. 
 
Presently, three mechanistic pathways are proposed for cross-presentation by HLA 
class I (Figure 1.3, (37)): The first model (Figure 1.3a) proposes that endocytosed or 
phagocytosed antigens are translocated into the cytosol, where they are degraded into 
antigenic peptides by the proteasome before being transported into the lumen of the 
ER by TAP. In the ER, the peptides are loaded onto nascent MHC class I molecules for 
   a    b    c 
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presentation at the cell surface. An important revision (Figure 1.3b) of the first model 
was made by studies showing that phagosome formation in macrophages and DCs 
might involve fusion with the ER, as the phagosomes contain ER-associated molecules 
such as calnexin, calreticulin, TAP and glucose-6-phosphatase, and Sec61. Sec61 is 
known to be involved in retrotranslocation of misfolded proteins from the ER to the 
cytosol for degradation, and thus it has been proposed that Sec61 might be involved in 
the translocation of proteins located in phagosomes to the cytosol. Recent findings 
provide evidence of an indispensable function for the early endocytic compartment in 
the cross-presentation of soluble antigens (Figure 1.3c) (32). Furthermore, this work 
establishes that recruitment of TAP to the early endosomal compartments is regulated 
by signaling through Toll-like receptor (TLR) 4 and MyD88 (32). Additional recent 
research demonstrates that human plasmacytoid DCs cross-present exogenous antigens 
to memory CD8+ T cells through the early endocytic compartment (33).  
 
 
Figure 1.4 HLA class II structure  (38). a) Side view of the complex composed out of the 
membrane-spanning α-chain (domains α1 and α2) and β-chain (domains β1 and β2). Peptide 
binding occurs in the groove between domains α1 and β1 (schematic). b) Peptide (red) bound in 
the peptide binding groove (top view; schematic). 
 
Peptide fragments binding on MHC class II molecules (Figure 1.4b, (38)) are generated 
in the endocytic pathway (39). The two polymorphic membrane-spanning chains α 
and β of HLA class II (Figure 1.4a, (38)) are synthesized into the lumen of the ER and 
associate with preformed trimers of the invariant chain (Ii) to form nonameric (αβIi)3 
complexes (40-42). Ii occupies the peptide-binding site of the HLA class II, therewith 
preventing premature peptide binding. Ii is also required to direct the complex out of 
the ER and to chaperone the HLA class II from the biosynthetic pathway to 
endosomes, either directly via the trans-Golgi-network or via the plasma membrane 
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(dominant) (43-45). Upon arrival in acidic endosomal compartments, the Ii luminal 
domain is progressively degraded by lysosomal proteases, breaking up the nonameric 
complex but leaving a contiguous internal segment of Ii, the class II-associated 
invariant-chain peptide (CLIP), associated to the peptide-binding groove of the now 
liberated HLA class II-αβ dimers (46). CLIP is then replaced from the peptide-binding 
groove by locally generated peptides of 9 to 25 amino acids, with the aid of the 
chaperone HLA-DM (47, 48). In contrast to HLA class I, the peptide binding groove of 
HLA class II is open at both ends and thus allows for binding of longer peptides with 
generally up to 25 amino acids ((38), www.syfpeithi.de). Although antigen loading 
occurs predominantly in late endosomes, some HLA class II-peptide complexes can be 
generated in early endosomes or lysosomes, or even at the plasma memrane (49-51). 
Macropinocytosis and degradation of pathogenic antigens into peptides is stimulated 
in maturing DCs (52, 53).  
CD8+ and CD4+ T cells are primed in the lymph nodes upon recognition of a specific 
non- or altered-self peptide presented by HLA class I or class II, respectively, together 
with costimulatory molecules on matured DCs, which have migrated into the lymph 
nodes after uptake of antigen (Figure 1.5, (54)) (55). Activated CD8+ and CD4+ T cells 
migrate into the periphery to exert their effector function as CTL or TH cells. 
Cytotoxicity is mediated by CTL through indirect killing of target cells by release of 
the cytokines TNF-α and IFN-γ, through induction of apoptosis in target cells via 
death receptor triggering (binding of the CTL-expressed Fas ligand FasL to the Fas 
receptor CD95, which is upregulated in target cells by IFN receptor signaling), or 
through direct killing of target cells by release of perforin and granzyme B into the 
intercellular space between CTL and target cell (56). TH1 cells secrete IFN-γ and 
interleukin (IL)-2 leading to activation of macrophages and CD8+ T cells (57). TH2 cells 
support a humoral immune response by secretion of IL-4 leading to activation of 
antibody secreting B cells and the complement system (58). Regulatory T cells (Treg), 
which are able to inhibit autoreative T cell responses, are also CD4+ and in addition 
constitutively express CD25 (59). 
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Figure 1.5 T cell induction by MHC class I and II antigen presentation (54). Antigen taken up 
by immature DCs in the periphery is processed and presented by matured DCs to naïve T cells in 
the lymphnodes in the form of MHC class I and II-peptide-complexes together with costimulatory 
proteins. Activated T cells proliferate and differentiate to effector T cells (CTL, TH, Treg), which 
exert their function in the periphery. 
1.1.3 Anti-viral immune response 
Since all viruses replicate within host cells, the main targets of innate immune 
recognition are viral nucleic acids, which are discriminated from self nucleic acids on 
the basis of specific chemical modifications and structural features that are unique to 
viral RNA and DNA, and on the basis of the cellular compartments where only viral 
nucleic acids are normally found (60, 61). This sensing of viral infection within cells 
results in the production of type I interferons IFN-α and IFN-β, which induce the 
General introduction 
 10
expression of more than hundred IFN-inducible genes both in the infected cell and in 
neighbouring cells by autocrine and paracrine IFN-mediated signaling, respectively 
(62-64). In addititon, a special subset of DCs, plasmacytoid DCs (pDCs), are triggered 
by the intracellular PRRs TLR3, TLR7/8 and TLR9 recognizing viral dsRNA (65), 
ssRNA (within endosomes) (66) and DNA (rich in CpG) (67, 68), respectively, which 
results in the production of systemic levels of type I IFN (69). Another type of DCs, 
myeloid DCs (mDCs), also express subsets of TLRs and, when stimulated, express high 
levels of IL-12, but little type I IFN (70). mDCs are crucial for the activation of  T cells 
during viral infections (71). 
The type I IFN-induced transcripts encode proteins that mediate the antiviral response 
(Figure 1.6, (72)). Some of these proteins (e.g., PKR and OAS) are enzymes whose 
activities are dependent upon viral co-factors (e.g., dsRNA). When such co-factors are 
provided, enzyme function evokes cellular changes, e.g., translational arrest. Other 
type I IFN-inducible factors trigger cell-cycle arrest (e.g., the G1/S phase-specific 
cyclin-dependent kinase inhibitor p21) and others promote the presentation of viral 
antigens to adaptive immune cells (e.g. by upregulating MHC class I and the antigen-
processing machinery). IFN-α/β also has immunomodulatory functions: promotion of 
DC maturation, upregulation of activities of NK cells and CD8+ T cells, and induction 
of synthesis of IL-15, a factor that promotes the division of memory CD8+ T cells.  
 
 
 
NK cells play an important role in bridging the innate and adaptive immune system 
during viral infections by mediating elevated cytotoxicity during early viral infetions 
Figure 1.6 Antiviral effects 
mediated by IFN-induced 
gene transcripts (72).  
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(73, 74). Upon priming by various soluble factors including type I IFN and by 
recognizing host stress proteins (MICA, MICB, ULBP1) by the NKG2D receptor, they 
can kill virus-infected target cells under particular conditions and boost the 
maturation and activation of DCs, macrophages, and T cells through a combination of 
cell surface receptors and cytokines including IFN-γ and TNF-α. Conversely, NK cells 
can also kill immature DCs, activated CD4+ T cells and hyperactivated macrophages. 
These NK cell regulatory functions are kept in balance by the recognition of 
constitutively expressed self molecules (e.g., MHC class Ia and MHC class Ib 
molecules) by means of inhibitory receptors (e.g., KIR or CD94-NKG2A).   
The early proinflammatory cytokine responses promote a classical TH1 response of 
mixed phenotypes with high IFN-γ, moderate IL-2, and low IL-4 levels, which leads to 
activation of macrophages, stimulation of CTL, and upregulation of MHC-based 
antigen presentation on DC (75). CD8+ T cell responses can be induced to extremely 
high levels with intense expansion. Activated CTL halt the spread of infection by 
killing virus-infected cells through direct cell-to-cell contact and by the release of 
soluble mediators (e.g., cytokines, such as IFN-γ and TNF-α, as well as perforin and 
granzyme) (76-78). In addition, antibody production (e.g., for neutralization of virus) 
by B cells is aided by CD4+ T cell cytokine responses (57, 58). 
1.1.3.1  Immune response to poxviruses 
The immune response against poxviral infections (see chapter 1.1.3.1) is reliable on 
IFN-γ and other TH1 cytokines provided by NK cells and macrophages to promote an 
effective CTL response including granzyme and perforin, and an effective antibody 
response (79). Recovery from secondary infection is dependent on the generation of 
neutralizing antibody.  
Viruses employ multiple strategies to evade or modulate the host immune system 
including antigenic variation (antigenic drift by mutations, or antigenic shift, e.g. 
Influenza virus), interference with antigen processing and presentation, modulation of 
cytokine production, prevention of viral antigen presentation, and abrogation of the 
induction of cell death. Vaccinia virus (VACV) secretes soluble proteins to bind the 
host cytokines (B15R), complement factors C3b and C4b, chemokines, interferons 
(B18R/B19R, B8R), and their receptors (80). Furthermore, the virus has strategies to 
inhibit intracellular antiviral effects of class I interferons (E3L, K3L; (81, 82)) and to 
interfere in various intracellular steps of the IL-1R and TLR signaling pathways, 
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ultimately regulating the NF-κB pathway and interferon regulatory factors (IRFs) 
(A52R, A4R, K1L, N1L; (83-85)). In addition, VACV produces proteins directly 
interfering with apoptosis of the host cell and thereby impairing CTL mediated lysis 
(F1L). 
1.1.3.2  The broad CTL response induced by poxviruses 
Immunization with VACV induces lifelong protection from smallpox disease and can 
serve as a benchmark for the type of immunity that other vaccines should induce. 
After immunization, CD8+ T cells are induced against VACV or attenuated strains such 
as MVA (see chapter 1.2.3.1) (86-88). They are polyfuctional (IFN-γ, MIP-1β, TNF-α, 
CD107a, IL-2, perforin, and granzyme), make much more IFN-γ than cells with fewer 
functions and express an unusual memory phenotype (CD45RO− CD27intermediate) (89). 
This polyfunctional CD8+ T cell profile is induced in response to both the vector and 
the inserts (see chapter 1.2.3.2) and is consistent with virus-specific CD8+ T cell 
responses observed in well-controlled persistent infections such as CMV, EBV, and 
nonprogressive HIV-1 infection (90-92). This suggests that maintenance of highly 
polyfunctional, virus-specific CD8+ T cells is beneficial and contributes to effective 
antiviral immunity. 
More than 200 human and mouse VACV- and/or MVA-specific CTL epitopes have 
been identified covering several different HLA alleles as well as the mouse alleles Kb,d 
and Db,d (79, 93-108). These epitopes have been found in about hundred different 
VACV/MVA proteins meaning that half of the VACV/MVA proteome is targeted by 
the cellular immune response (93). Two thirds of the proteins contain a single epitope, 
while 10% of the antigenic proteins contain three or more epitopes. This broad 
epitope repertoire is contrary to smaller genome viruses which exhibit marked 
immunodominance (109).  
Although a high number of CTL epitopes has been identified by many different 
research groups, there was only little overlap between the studies (93, 110). Several 
reasons could explain this observation: first, most groups attempted to narrow their 
focus to a selected group of antigens; second, different virus strains (permissive and 
non-permissive), different model systems (humans and HLA-transgenic mice (110)), 
and different methods (T cell screening by IFN-γ ELISPOT, Tetramer-staining, 
intracellular cytokine staining and HLA ligand analysis) were used for the analyses; 
third, vaccinations modes (prime and boost), routes of infection, virus dose and time 
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points of analysis after vaccination were inconsistent (93). For example, analyses using 
permissive versus non-permissive strains, prime- versus boost-vaccinations, T cell 
screening versus HLA ligand analysis are likely to detect different percentages of CTL 
primed by cross-presentation and by direct presentation (111, 112). 
1.1.3.3  Identification of viral T cell epitopes 
Essentially, two basic methodologies are being employed for identification of T cell 
epitopes, which are either based on identification of epitope-specific T cells in 
peripheral blood mononuclear cells (PBMCs) of immune donors, or on sequencing of 
viral MHC ligands isolated from virus-infected cells: 
The first method to identify T cell epitopes uses stimulation of PBMC of immune 
individuals followed by the measurement of the T cell response ex vivo or after 
expansion of low abundant memory T cells by peptide stimulation or of naïve T cells 
by in vitro priming. Analyzed are cytokine production (by intracellular cytokine 
staining (ICS; e.g. IFN-γ) or by IFN-γ-enzyme-linked imunosorbent spot assay 
(ELISPOT)), cytotoxicity (by chromium (51Cr) release “kill” assay or granzyme B-
ELISPOT) or presence of TCR-specific T cells (by tetramer staining) (113-116). Several 
techniques have been utilized to screen PBMC, including genome wide scanning 
(117), phage display/DNA libraries (118, 119), combinatorial peptide libraries (120-
122) and expression cloning strategies (123). Less PBMC have to be screened by 
predicting peptides that may bind on a certain MHC allele using computer algorithm-
based epitope prediction, for example SYFPEITHI (www.syfpeithi.de, (124)) and 
Bimas (www-bimas.cit.nih.gov/molbio/hla_bind) (125-128). The bioinformatic 
algorithm of SYFPEITHI is based on identified amino acids commonly occurring at 
anchor positions in naturally MHC-presented peptides, whereas the algorithm of 
Bimas is based on binding studies of synthetic peptides. Using this still quite laborious 
approach, immunodominant epitopes are detected that are frequent in the population 
and induce a measurable T cell response in vitro. However, detection is often 
restricted to the most immunogenic viral epitopes. Epitopes resulting from 
posttranslational modifications or frame shifts are not detected. A more recent 
development in screening of PBMC is the identification of T cell responses by the 
loading of HLA tetramers with arrays of peptides using conditional HLA ligands (129). 
This technique allows for rapid high throughput detection of epitope-specific T cell 
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responses. Like all other approaches based on flow cytometry, this method enables 
only detection of frequent CD8+ T cells (>0.01% of CD8+ cells).  
The second methodology is based on isolation and sequencing of viral HLA ligands 
from cells infected in vitro by mass spectrometry (MS) (130-134). An analytical 
approach to apply MS for the identification of viral epitopes in the plethora of self-
epitopes was first described using an in silico subtractive method, which compares the 
MS spectra from infected cells and non-infected cells (132). The sensitivity of the 
technology was considerably improved through the use of stable isotopes, for example 
by the SITE technology (stable isotope tagging of epitopes) for the detection of viral 
HLA class I epitopes (133) and a similar strategy for identification of class II epitopes 
(135). SITE is based on metabolic labeling of endogenously synthesized proteins 
during infection and can therefore not be utilized to identify MHC ligands from 
infected organisms. MS-based approaches are generally less biased than T most cell-
based methods, since no predictions are used and immunogenic epitopes of all viral 
proteins are detected irrespective of inducing a detectable T cell response in an 
individual. However, MS analyses imply a technical bias: individual peptides might 
not be detected by the mass spectrometer and for detection of low abundant viral 
MHC ligands sensitive instrumentation and high numbers of infected cells may be 
needed. Yet, epitopes resulting from posttranslational modifications or frame shifts 
may be detected. Most importantly, only MHC ligand analysis identifies the epitopes, 
which are actually presented by infected cells and which thus may provide protection 
from infection. 
Mass spectrometry also enabled estimates of the abundance of individual peptides on 
the cell surface and of the complexity of the overall repertoire. By standardizing 
against the ion current of known amounts of model peptides spiked into extracts, 
many MHC-peptides have been estimated at one copy or less per cell (136, 137), at 10 
to 400 copies per cell (138, 139), and a single viral peptide from cells infected with 
measles virus has been found at 100,000 copies per cell (132). The number of peptide-
MHC complexes required for T cell recognition varies from several thousand per 
target cell to as few as one (137, 140-145). Some studies have shown a direct 
correlation between cell surface densities of individual peptide antigens and the 
magnitude of the immune response to them (146-150), but other studies have shown 
exactly the opposite (132, 137, 151). Higher doses of peptide antigen can actually 
reduce the magnitude of an immune response in vivo (132, 152). Finally, there are 
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examples of self-peptides that become antigens on cancer cells (153, 154), suggesting 
that the immune response may be initiated because their level of presentation is 
altered.  
Criteria to rate how ‘defined’ a potential epitope is, which has been found by any of 
the described approaches, have been proposed by Yewdell (155):  
- No star: Responses are measured by overlapping peptides; no effort is made to 
characterize determinants in a systematic manner. 
- One star Î: The highest affinity peptide in a suspected peptide sequence is 
determined by testing various lengths of synthetic peptides compatible with class I-
binding algorithm predictions, and peptides bind to class I molecule with a KA of <10-7 
M or activate CD8+ T cells at concentrations of <10-9 M. CD8+ T cells induced by the 
peptide are shown to recognize histocompatible cells expressing the source protein. 
While this evidence provides confidence that cells can generate the determinant from 
its source protein, it is not definitive, since CD8+ T cells might still cross-react with 
another peptide from the same protein. 
- Two stars ÎÎ: One-star criteria plus one of the following: peptides eluted from cells 
co-elute with the synthetic putative peptide via HPLC analysis that offers reasonable 
discrimination between distinct peptides. Half-star bonus for using multiple solvent 
systems to increase the resolution of peptide separation, or for demonstrating that 
CD8+ T cell recognition of cells synthesizing source protein is abrogated by introducing 
a missense mutation into the sequence encoding the putative determinant, with 
another half-star bonus for introducing the mutation into the source pathogen itself. 
- Three stars ÎÎÎ: Two-star criteria plus mass spectroscopy identification of 
determinant from source-organism-infected cells. 
- Four stars ÎÎÎÎ: Three-star criteria, but attained using cells directly obtained 
from animals infected with the source organism.  
1.1.4 Anti-tumor immune response 
Certain human tumors, particularly melanoma and renal cell carcinoma (RCC), can 
occasionally undergo spontaneous regression (156, 157). Several observations support 
the view that CTL are the major anti-tumor effectors in humans. First, 
immunosuppressed transplant recipients display higher incidences of non-viral 
tumors, such as melanomas, colon, lung, pancreas, bladder, kidney, and endocrine 
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system cancers, than immunocompetent control populations (158). Second, the 
presence of lymphocytes within the tumor is often a positive prognostic indicator of 
patient survival (159). Third, a minority of cancer patients (<5%) are able to develop 
spontaneous innate and acquired immune responses to the tumors they bear (160, 
161). Therefore, stimulation of tumor-specific CD8+ T lymphocytes  has become the 
focus of many clinical trials (so called ‘cancer immunotherapy’), in which multiple 
antigen delivery strategies have been tested in hundreds of patients (summarized in 
(162)). These trials have demonstrated that vaccines are safe, immunogenic, and yield 
a low frequency of objective clinical responses. Several immune evasive mechanisms 
account for a limited effectiveness of endogenous or vaccine-induced immune 
responses to tumors (Figure 1.7, (163, 164)). Induction of a broad immunity to 
multiple tumor-associated antigens (TAAs), and activation of persistent T cells may be 
important. Additional modes of amplifying immune responses (lymphodepletion, 
cytokine support, inhibition of negative immune self-regulation) are now being tested 
and should improve clinical responses from 5-10% response seen currently (162). 
Importantly, CD4+ TH cells have been shown to be required for generating and 
maintaining potent antitumor immunity (165).  
 
Figure 1.7 Mechanisms that limit immune responses against tumors (163).  
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1.1.4.1  Tumor-associated antigens 
Peptide antigens associated with MHC class I or class II molecules are the molecular 
targets for T cell recognition of cancer. Since, in 1991, the first molecularly defined 
human TAA recognized by CTL was described (166), several studies utilizing 
expression cloning of TAA cDNAs, reverse immunology, HLA ligand analysis, genetic 
approaches, and serological identification of antigens by recombinant expression 
cloning (SEREX) have been performed to identify a number of TAAs, which can be 
presented by HLA class I and II on tumor cells or APCs ((167-171), 
www.cancerimmunity.org/peptidedatabase/Tcellepitopes). Reverse immunology refers 
to prediction of epitopes from an already identified TAA on the basis of known HLA-
peptide motifs. HLA ligand analysis involves eluting and fractionating of TAA peptides 
naturally presented by HLA on tumor cells by reverse-phase high performance liquid 
chromatography (HPLC) and mass spectrometry (MS) (LC-MS/MS). Genetic 
approaches are used to identify tumor genes coding for the epitopes recognized by 
isolated patient T cell clones reactive against autologous tumors. SEREX is based on 
the recognition of TAA by cancer patients’ autologous sera. According to the pattern 
of expression in neoplastic and normal tissues, TAAs can be classified into five major 
categories: 1) proteins expressed only in testis/placenta (which lack HLA expression), 
2) proteins specific for the (tumor) tissue, 3) proteins with altered amino acid 
sequence, 4) proteins derived from oncogenic viruses (for example, herpesviruses) 5) 
ubiquitous proteins over-expressed in tumor cells, 6) proteins with tumor-
associated/specific alterations in posttranslational modification of amino acid side 
chains ((162, 172-176), Table 1.1).  
For cancer immunotherapy it has to be taken into account that TAAs, which are 
highly overexpressed in tumor tissue but are also found in at least some normal tissues, 
bear the risk of inducing autoimmunity in contrast to TAA, which have emerged by 
mutation. TAAs are generally tumor- and patient-specific. In addition, presentation of 
epitopes is dependent on the patient’s set of HLA alleles. Cancer immunotherapy is 
therefore a rather individual therapy against tumors. 
Most TAAs used for epitope-based cancer immunotherapy are considered to be ‘self-
antigens’. Therefore, one of the main challenges is to effectively and safely break 
tolerance to TAA, for example by adjuvants, addition of heterologous helper peptides, 
inclusion of cytokines, autologous DCs pulsed with different TAAs, adoptive transfer 
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of ex vivo cultured effector T cells, or viral vectors producing a set of epitopes in 
parallel to viral antigens (162).  
 
Table 1.1 Tumor Antigen Categories 
TAA category Antigen characteristics Genes 
Cancer - testis Expressed in various tumors but not normal 
tissues except testis and placenta 
MAGE, GAGE, BAGE,        
NY-ESO-1 
Differentiation Shared between tumors and normal tissues 
from which they arose 
Tyrosinase, Melan-A/MART-
1, gp100, TRP-1, TRP-2 
Tumor-specific Generated by point mutations or splicing 
aberrations in ubiquitous genes 
p53, Ras, CDK4, β-catenin, 
TRP-2/INT2 
Tumor virus Produced by oncogenic viruses (e.g., HPV) HPV16 E7 
Tumor-
associated 
Over-expressed in histologically different 
types of tumors 
Survivin, MUC1/2, AFP, 
EphA2 
Posttranslational 
modification 
Containing altered posttranslational 
modification in malignant cells 
glycosylated MUC-1, 
tyrosinase(D370N),         
β-catenin(pS33), 
IRS2(pS1100) 
 
One subclass of the sixth category of TAAs (Table 1.1) is special in the way that they 
are not defined by altered protein expression but by altered cellular signaling, and 
thereby they are directly linked to cellular growth control processes: proteins 
differentially modified by posttranslational phosphorylation in transformed cells 
compared to non-malignant cells (176, 177). Degradation of these proteins generates 
so called phosphopeptides that are uniquely or differentially presented on malignant 
cells by MHC class I molecules. CTL against tumor-specific phosphopeptides derived 
from some of these proteins have been generated and their ability to selectively 
recognize tumor cells has been demonstrated ((176), see chapter 1.1.4.2). Three 
observations support an intensified search for phosphopeptide epitopes as TAA 
candidates for cancer immunotherapy. First, malignant transformation leads to 
alterations in protein kinase pathways regulating cell growth, differentiation, and cell 
death (136, 178). Second, deregulated signaling cascades often lead to increased 
protein phosphorylation (179). Third, rapid protein degradation by the proteasome is 
an important mechanism for regulating the activity of many transcription factors, cell 
growth modulators, signal transducers, and cell cycle proteins (171, 180, 181). This 
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degradation often depends on E3 ubiquitin-ligases whose activity in turn depends on 
phosphorylation of the target protein (21, 22, 171). 
Signalling pathways and hence phosphorylation of proteins might be changed by 
several ways in the case of cellular transformation. First, up-regulation of 
phosphorylation at specific sites has been associated with transformation. Certain 
phosphorylation sites in some proteins become constitutively phosphorylated during 
oncogene activation, for example, in c-Jun and in the tumor suppressor gene product 
p53 (182). c-Jun becomes activated by phosphorylation of the two serines S63 and S73, 
and has been reported to be phosphorylated in both leukemia and lung cancer cells. 
Phosphorylation of the p53 tumor suppressor protein has been described for a number 
of serine residues, among these S9, S15, S37, S315, S392, and S378 (183, 184). Second, upon 
the critical event resulting in activation of the transforming phenotype, some 
protooncogenes characteristically acquire novel kinase activities leading to the 
appearance of novel phosphorylation sites (185, 186). For example, in leukemia, c-abl 
protooncogene becomes activated by its translocation to chromosome 22 giving rise to 
a BCR-ABL fusion protein (136, 187). A crucial difference between the fusion protein 
and the normal c-abl is that only the chimeric protein exhibits tyrosine kinase activity 
(185), resulting in autophosphorylation of a number of tyrosine residues of the BCR-
ABL fusion protein (136, 188), as well as causing a constitutive increase in tyrosine 
phosphorylation of other cellular proteins. Third, transformation-associated 
posttranslational modification of a cellular protein might alter the pattern of peptide 
fragments that are generated from it.  
1.1.4.2  HLA ligands with differential posttranslational modifications as CTL 
inducers - phosphopeptides 
Only little is known about the effect of naturally occurring posttranslational 
modifications of peptides on MHC class I restricted antigen presentation in vivo. They 
may affect antigen processing, MHC binding, and interaction with the TCR. So far, it 
has been described that T cells can specifically recognize MHC class I  and class II 
restricted peptides which have been posttranslationally modified (189-191). MHC class 
I presented peptide modifications include change of asparagine to aspartate (175), 
modification of cysteine (192), glycosylation of serine (174, 193, 194), and 
phosphorylation of serine, threonine or tyrosine (176, 195, 196).  
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It has been shown, that phosphorylated peptides can be transported by TAP, can bind 
to MHC class I molecules, and can be discriminated by CTL from the corresponding 
unphosphorylated ligands (195). Naturally processed HLA class I ligands have been 
identified from several cell lines by LC-MS/MS (196), and CTL against HLA-presented 
phosphopeptides specifically found on tumor cell lines have been detected (176).  
Consistent with the ability of CTL to discriminate between phosphorylated and non-
phosphorylated peptides, molecular modeling of one of the HLA-A*0201 
phosphopeptide complexes suggests that the phosphate moiety is accessible for the 
TCR (Figure 1.8, (177)). Moreover, the prominence of this functional group and its 
electronegativity may make it an effective immunogen eliciting a diverse CTL 
response. Whereas some phosphopeptides are involved in TCR contacts, others may 
enhance binding to the HLA. The solution of HLA-bound phosphopeptide structures 
in complex with specific T cell receptors has not been shown so far. 
 
 
Figure 1.8 Structural model of HLA-A*0201 complexed to the 
phosphorylated peptide RTLpSHISEA (177). The phosphate 
moiety points away from the HLA binding groove. 
 
Phosphorylated HLA ligands are of great interest, since phosphorylation of tyrosine, 
serine, and threonine residues (Figure 1.10a) by cellular kinases is a tightly regulated 
posttranslational cytosolic event, which can be deregulated by inflammation, 
intracellular infection, cellular activation, and malignant transformation. This may 
result in the generation of sufficient amounts of phosphopeptides for presentation on 
HLA to induce T cells (see 1.1.4.1). Moreover, a large number of phosphorylated viral 
proteins have been characterized, which also might generate phosphopeptide 
fragments for HLA presentation. Viruses with multiple known protein 
phosphorylation sites include EBV, adenovirus, HIV, and influenza virus (197-199).  
Several phosphorylation sites of proteins and their functional roles are known 
(www.phosphosite.org). The identified phosphorylated HLA ligands have added 
several novel ones to the list (176, 196).  
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1.1.4.3  Identification of phosphorylated HLA ligands 
Stoichiometry of protein phosphorylation is often low. Therefore, in a standard LC-
MS/MS experiment, the chance of detecting and sequencing phosphopeptide MHC 
ligands is quite low. Phosphopeptide enrichment is consequently a prerequisite to 
study phosphorylation on a global level.  
Several phosphopeptide enrichment methods have been developed in the field of 
proteomics (200): 1) Antibodies raised to phosphorylated residues that are 
independent of the surrounding sequence can be used to purify phosphorylated 
proteins and peptides (201, 202). 2) Immobilised metal affinity chromatography 
(IMAC) is the most widely used method for enriching phosphorylated peptides or 
proteins (203). The positive charge of transition metals such as Ga3+ or Fe3+ bind 
negatively charged phosphate groups with high affinity (Figure 1.9a) and elution is 
readily achieved by competition with sodium phosphate or EDTA. 3) Metal oxide-
affinity purification (MOAC) is particularly performed with titanium dioxide (TiO2) 
(204) (zirconium and aluminum metal oxides are also applied (205, 206)) used in the 
form of poros TiO2 beads or microspheres (Figure 1.9b). Phosphopeptides bind at low 
pH. Specificity has been further improved by adding 2,5-dihydroxybenzoic acid 
(DHB). Elution is achieved at high pH with ammonium bicarbonate or hydroxide 
(207). 4) Strong cation exchange chromatography (SCX) separates proteins or peptides 
based on their solution charge state. At low pH, phosphopeptides are charged more 
negatively because of the negative phosphate group and therefore elute earlier in a salt 
gradient than non-phosphopeptides (208). Phosphorylated MHC ligands have been 
enriched by Fe3+-based IMAC, so far (176, 196). 
In addition to these native phosphorylation strategies, several chemical derivatisation 
strategies have been developed exploiting various aspects of phosphate groups, such as 
their labile nature and the subsequent reactivity of the dephosphorylated group to 
nucleophiles, for tagging (200, 209). Other chemistries such as methyl-esterification 
were developed to improve the specificity of metal affinity chromatography (210). 
Additionally, methyl-esterification may be used to isotopically label peptides for 
relative quantification purposes (209, 211). 
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Figure 1.9 Phosphopeptide enrichment. a) Fe3+-based IMAC (203); b) TiO2-based MOAC (207) 
 
Phosphorylation of amino acid side chains often shows greater susceptibility to 
cleavage by collision-induced fragmentation (CID) in MS than the peptide backbone 
(200). This characteristic may be used in different analytical strategies: 1) Detection of 
the low mass ‘marker’ ions generated from the modification itself, 2) Detection of the 
loss of the modification from the peptide precursor.  
In positive ionisation CID MS/MS experiments, phosphopeptide ions are labile and 
thus produce a significant neutral loss of phosphoric acid (H3PO4), corresponding to 
mass depletion of 98 Da, via gas-phase β-elimination from phosphoserine and 
phosphothreonine residues (200), and less often a neutral loss of HPO3 corresponding 
to mass depletion of 80 Da (Figure 1.10b, c). The number of phosphate groups on the 
phosphopeptide can be determined from the frequency neutral loss occurs from the 
precursor ion. Unique product ions of dehydroalanine (69 Da) from phosphoserine 
(pS), and dehydroaminobutyric acid (83 Da) from phosphothreonine (pT) are 
generated (200).  
Techniques such as precursor ion monitoring, neutral loss monitoring and neutral loss 
triggered MS3 fragmentation are frequently applied in phosphopeptide MS-analysis  
(200). Phosphotyrosine (pY)-containing peptides yield a characteristic immonium ion 
at m/z 216.04 in the positive ion mode (Figure 1.10d). When phosphopeptides are 
fragmented in the negative ion mode, a characteristic product ion (PO3-) is generated 
giving rise to a peak at m/z 79 in the product spectrum (Figure 1.10c). These two 
precursor ion-scanning modes are most commonly implemented on triple quadrupole 
mass spectrometers.  
a   
 
                    
 
 
 
 
 b 
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Figure 1.10 Phosphopeptide characteristics. a) Phosphorylated amino acids; b) Neutral loss of 
98 Da from phosphoserine (equivalently for phosphothreonine, not shown); c) Generation of the 
negative precursor ion -79 Da / neutral loss of HPO3, 80 Da; d) Phosphotyrosine immonium ion 
generated by a combination a- and y-type-cleavge. 
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1.2 Vaccinia Virus  
1.2.1 Poxviridae - Orthopoxviruses 
1.2.1.1  Classification 
The Poxviridae comprise a family of complex DNA viruses that replicate entirely in 
the cytoplasm of vertebrate or invertebrate cells (Figure 1.11). 
 
 
Figure 1.11 Taxonomy of main viruses infecting humans (based on the International 
Committee on Taxonomy of Viruses Database (ICTVdB)) 
 
The distinguishing properties of the family Poxviridae include a cytoplasmic site of 
replication and a large complex virion, which contains enzymes that synthesize 
mRNA and a genome composed of a single linear dsDNA molecule of 130 to 300 kb 
containing nonoverlapping genes and a hairpin loop at each end. Poxviruses are 
divided into the subfamilies Chordopoxvirinae and Entomopoxvirinae, based on 
vertebrate and insect host-range (Figure 1.12). DNA sequencing and bioinformatic 
analysis confirm the genetic relationship between the poxvirus subfamilies.  
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Figure 1.12 Poxvirus phylogenetic tree as described in (212): Branch lengths are not to scale. 
Taxonomic groups are labelled and shaded. The term "clade II" poxviruses is refers to the group 
of yatapox, deerpox, capripox and suipox, as per convention (213). Numbers above branches are 
percent bootstrap values, numbers below the branches indicate the percentage of gene trees 
that supported the branch. 
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The subfamily of Chordopoxvirinae consists of eight genera: Orthopoxvirus, 
Parapoxvirus, Avipoxvirus, Caripoxvirus, Leporipoxvirus, Suipoxvirus, 
Molluscipoxvirus, and Yatapoxvirus. Members of the same genus are closely related 
genetically and have a similar morphology and host-range. Two members of this 
family, smallpox causing variola virus (VARV) and the dermatotropic molluscum 
contagiosum virus (MOCV), are obligate human pathogens, but others can be 
transmitted from animals to humans as zoonoses.  
Orthopoxviruses have been studied intensively. The prototype orthopoxvirus vaccinia 
virus (VACV) has been propagated as the smallpox vaccine for 200 years.  VACV has a 
broad cellular tropism in vitro and potential host-range in vivo, but there is no clearly 
identified animal reservoir for the virus in nature. VACV was the first animal virus 
seen microscopically (Figure 1.12), grown in tissue culture, accurately tittered, 
physically purified, and chemically analyzed.  
         
Figure 1.13 Poxvirus morphology. a) First microscopic documentation of VACV (214); 
b) Electron microscopic image of VACV (215); c) Thin section of CPXV (electron 
microscopy by Frank Fenner). lb, lateral bodies; c, core; bar  represents 100 nm 
DNA sequencing reveals that genes common to VARV, ectromelia virus (ECTV), 
camelpoxvirus (Figure 1.14, (215)), VACV, and cowpoxvirus (CPXV) are greater than 
90% identical. CPXV contains all genes present in other orthopoxviruses, suggesting 
that it most closely resembles the ancestral member of this genus, whereas the other 
orthopoxviruses have lost genes. 
 
Figure 1.14 Examples of host-restricted poxviruses (215). Some poxviruses, like variola virus  
(smallpox) (a), ectromelia virus (mousepox) (b) or camelpoxvirus (c) remain largely restricted to 
one host species and rarely, if ever, cause zoonotic infections outside that species. Other 
poxviruses can infect multiple zoonotic host species. 
a b c
General introduction 
 27
1.2.1.2  Virion structure 
Virions of poxviruses are large compared to other animal viruses (360 x 270 x 270 nm) 
(Figure 1.13b). They are generally brick-shaped, or pleomorphic and consist of a 
lipoprotein structure, the outer membrane, a biconcave core, and lateral bodies (Figure 
1.13c). During replication, two infectious forms of virus are produced: intracellular 
mature virion (IMV) and extracellular enveloped virion (EEV), which acquires an 
additional envelope composed of host cellular membrane and virus-specific proteins.  
1.2.1.3  Virus entry into host cells 
VACV mature virions (MVs) use macropinocytosis and apoptotic mimicry to enter 
host cells (216): Virus particles move along actin-containing filopodia to the cell body, 
where they are internalized after inducing the extrusion of large transient membrane 
blebs. The induction of blebs, the endocytic event, and infection are all critically 
dependent on the presence of exposed phosphatidylserine in the viral membrane. 
Surface-exposed cellular phosphatidylserine triggers the uptake of cellular apoptotic 
debris (217). Late-stage vaccinia-infected cells undergo apoptosis. MV spread is 
therefore likely to be connected with apoptosis and a preprogrammed macropinocytic 
response of neighboring cells to apoptotic bodies. This allows the virus to enter many 
different cell types, because phosphatidylserine-mediated clearance of apoptotic 
material is common to most cells (217, 218). By mimicking an apoptotic body, MVs 
may avoid immune detection as they spread to surrounding cells, because 
macropinocytosis of apoptotic debris suppresses the activation of innate immune 
responses (218).  
1.2.1.4  Virus replication 
The virus replicates and matures in the cytoplasm of the host cell within so called viral 
factories, distinct sites that are surrounded by membranes derived from the rough ER 
that support viral replication  (Figure 1.15, (215)) (219, 220). Fully permissive viral 
replication is characterized by three waves of viral mRNA and protein synthesis 
(known as early, intermediate and late), which are followed by morphogenesis of 
infectious particles (221). This type of genetic programming is known as a cascade 
mechanism, because the products of each stage regulate the next. A complete early 
transcription system is present within the core of the virus particle, providing a 
mechanism for the synthesis of viral early mRNA soon after infection and accounting 
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for the fact that purified poxvirus DNA is not infectious. VACV encodes its own 
enzymes and proteins required for gene transcription, genome replication, virion 
production, and morphogenesis and, for the most part, does not depend on host cell 
proteins for these processes. In addition, VACV infection induces a rapid and massive 
shutdown of host gene expression that acts at several levels (222-225). 
 
 
Figure 1.15 Fully permissive poxvirus replication cycle (215). EEV, extracellular 
enveloped virion; IMV, intracellular mature virion; IEV, intracellular enveloped virion 
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Following entry into the cytoplasm, virus cores are transported on microtubules to 
sites of transcription, and mRNA transcription is detected within 20 minutes (226). 
After the core is released into the cytoplasm, early mRNAs encode growth factors, 
immune defense molecules and enzymes and factors needed for replication of the viral 
DNA and for transcription of the intermediate class of genes (221). About half of the 
viral genome is transcribed prior to DNA replication (227). The core is uncoated and 
DNA replication begins 1-2 hours after infection and results in the generation of about 
10,000 genome copies per cell (228). Following DNA replication, intermediate gene 
transcripts encode enzymes and factors for late gene expression. Products of the late 
genes form virion structural proteins, enzymes including RNA polymerase, and early 
transcription factors (221). 
Assembly begins with the formation of discrete membrane structures (229). The 
concatemeric DNA intermediates are resolved into unit genomes and are packaged in 
immature virions. Maturation proceeds to the formation of infectious IMV. These are 
wrapped by modified trans-Golgi and endosomal cisternae and are then transported to 
the periphery of the cell along microtubules. Fusion of the wrapped virions with the 
plasma membrane results in release of EEV. After fusion with the plasma membrane, 
stimulation of actin tails beneath extracellular virion particles acts to enhance cell-to-
cell virus spread (230). 
1.2.1.5  Gene expression 
Expression kinetics have been described for a variety of the 223 annotated VACV 
genes. These studies, and work done to define promoters and transcription complexes, 
have led to the definition of four temporal gene classes and three distinct promoter 
types. The promoters have been named early, intermediate, and late, with each 
promoter associated with one gene class (221). In addition, some genes have elements 
of early and late promoters in their upstream region, giving rise to a fourth class 
referred to as early/late.  
A recent analysis of expression kinetics using a genome tiling array approach has 
revealed another class of genes: 35 genes of mostly unknown function exhibited 
immediate-early expression (Figure 1.16, (231)).  
All poxvirus genes consist of a continuous open reading frame (ORF) and there is no 
evidence of RNA splicing (221). 
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Figure 1.16 Function and expression levels of genes in the different classes (231). 
A) The four gene classes with the fraction (%) of each class having a certain function 
indicated. B) Groups of genes associated with a specific function, with the fraction (%) 
of each group belonging to each kinetic class indicated. C, D) Median ORF expression at 
each time point for genes within each functional category (C) and kinetic class (D). 
1.2.2 Smallpox Disease and its eradication by VACV-based 
vaccination 
Smallpox disease is believed to have originated over 3,000 years ago in India or Egypt. 
For centuries, repeated epidemics swept across continents, decimating populations and 
profoundly influencing human history.  
The disease is caused by VARV and was a febrile rash illness and had two main forms: 
variola major and variola minor (World Health Organization (WHO), www.who.int/ 
mediacentre/factsheets/smallpox/en/), both forms showing similar lesions. The disease 
followed a milder course in variola minor, which had a case-fatality rate of less than 
1%. The fatality rate of variola major was around 30%. Between 65–80% of survivors 
were marked with deep pitted scars (pockmarks), most prominent on the face. 
Blindness was another complication. No effective treatment was ever developed 
against the disease.  
In 1798, the English physician Edward Jenner reported the observation, that infectious 
agent, which caused lesions on the skin and mucosal surfaces on cows and their 
human caretakers could be used to prevent smallpox infection (232). This process, 
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termed variolation, involved the intentional introduction of dried CPXV induced 
pus/scabs into healthy individuals and led to a more benign course of disease with a 
death rate of approximately 1%. This was the beginning of both the eventual 
eradication of VARV and of vaccination in general. The vaccination procedure was 
later refined so that people were inoculated with pure preparations of live VACV, an 
orthopoxvirus of unknown origin, closely related to VARV and CPXV, and containing 
sufficient antigenic cross reactivity to provide protection from VARV. In 1977, 
through a world-wide vaccination campaign headed by the WHO, VARV was 
declared eradicated (233, 234). The seed virus (VACV strain Lister Elstree) used to 
produce the vaccine is being held for WHO by the WHO Collaborating Centre for 
Smallpox Vaccine in Bilthoven, the Netherlands. 
Vaccination usually prevents smallpox infection for at least ten years (WHO). If 
symptoms appear, they are milder and mortality is less in vaccinated than in non-
vaccinated persons. Even when immunity has waned, vaccinated persons shed less 
virus and are less likely to transmit the disease. 
1.2.2.1  Adverse effects of VACV vaccination 
VACV-based smallpox vaccination has some adverse effects (235-238). Historically, 
14-52 people per million primary vaccinees had serious or life-threatening adverse 
reactions to the vaccine, and one to two people per million died because of the 
vaccine. Serious side-effects included inadvertent inoculation, eczema vaccinatum, 
progressive vaccinia, fetal vaccinia, generalized vaccinia, and erythema multiforme 
major. In particular, VACV occasionally infects the brain and causes postvaccinal 
encephalitis, which can be lethal or result in permanent brain damage.  
Consequently, as smallpox became rarer, the dangers of vaccination began to outweigh 
its benefits. Routine smallpox vaccination stopped in the US in 1972, and in 1980 the 
World Health Organization recommended that all countries stop vaccination.  
1.2.2.2  Inflammative autoimmune myocarditis 
Individual cases of cardiac complications, including myocarditis, pericarditis, and 
arrhythmias were reported in the four decades before routine vaccination was 
stopped, usually diagnosed after death, since cardiac enzymes and echocardiograms 
used to diagnose myocarditis today were unavailable in the 1960s and 1970s (239, 
240). Most reports were from Europe and Australia, where the VACV strain Lister 
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Elstree was used, which was thought to be more “reactogenic” than the New York City 
Board of Health (NYCBOH) strain (Dryvax®; Wyeth Laboratories Inc, Marietta, Pa) 
used in the US (235).  
However, during a Dryvax®-based smallpox vaccination campaign in the US started in 
December 2002 (see chapter 1.2.3.1), the frequency of adverse events that was 
anticipated on the basis of historical data was lower than expected, but there were 
higher-than-anticipated vaccination-related myopericarditis cases, which led to much 
publicity of and controversy about the program (134, 236, 241). Autoimmune 
eosinophilic-lymphocytic myocarditis could be diagnosed in vivo by biopsy shortly 
after vaccination providing histological evidence for eosinophil-mediated cardiac 
myocyte necrosis (242). The lymphocytic component consisted mainly of CD3+ T cells, 
of which about 25% were CD8+. PCR showed that myocytes were virus-free.  
1.2.3 The impact of Orthopoxviruses today 
1.2.3.1  The new fear of smallpox disease – vaccine update 
By the end of 1983 all known remaining stocks of VARV were held in only two WHO 
Collaborating Centres - the U.S. Centers for Disease Control and Prevention (CDC) in 
Atlanta, Georgia, and the Research Institute for Viral Preparations in Moscow, Russia 
(in 1994, the Russian stocks were transferred to Kotsovo, Russia) (233).  After 9/11 and 
the anthrax letters, however, there is concern that VARV may exist outside the WHO 
designated repository laboratories and may be used as a bioweapon (243). If this 
happened, exposed individuals and their contacts, possibly even whole populations, 
would have to be vaccinated as quickly as possible, since today very few people are 
probably fully protected against smallpox (244, 245).  
Even if VARV never again infects humans, there are other poxviruses that can cause 
serious human disease. In 2003, an outbreak of human monkeypox occurred in the US 
due to the inadvertent importation of monkeypox virus (MPXV) in a shipment of 
rodents from west Africa (246, 247). An even more pathogenic variant resulting in 
mortality rates of 10–15% is found in central Africa (113, 248, 249). The animal 
reservoir for MPXV in Africa remains unknown, although several indigenous 
members of the squirrel species are likely candidates, but the features that predispose 
this virus to zoonotically infect man and other primates are unknown. If MPXV were 
General introduction 
 33
to establish a reservoir status in a susceptible north American rodent species, such as 
prairie dogs (250), the public health consequences would be considerable.  
For these eventualities, many countries still have stockpiles of first-generation calf-
lymph-derived smallpox vaccines, but these contain different VACV strains causing 
different frequencies of adverse effects (236, 238).  
In October 2002, the US Department of Defense recommended smallpox vaccine for 
eligible volunteers whom public health authorities might designate to investigate 
initial smallpox cases. Then, in December 2002, a large-scale smallpox vaccination 
program, mainly involving army and health care personnel, but also interested 
civilians, has been started (134). The program is still ongoing with more than 1 million 
having been vaccinated so far. Unexpected issues, such as the development of 
vaccination-related myopericarditis were discovered during the implementation of 
this program (134, 241, 251). 
The smallpox vaccines currently licensed in the USA and UK are live, attenuated 
VACV derived from calf lymph (Dryvax®, last produced in 1982 by Wyeth), a first-
generation vaccine (238). Although this type of vaccine was used to eradicate smallpox 
worldwide, previous manufacturing methods using calf lymph are no longer 
acceptable because of the absence of controls in the process and the potential risk of 
contamination with the infectious agent associated with the prion disease bovine 
spongiform encephalitis.  
Therefore, a second-generation cell-cultured smallpox vaccine (CCSV) produced by 
using the NYCBOH or Lister-Elstree VACV strains have been developed and seem to 
be a safe and immunogenic alternative to the first-generation calf-lymph derived 
vaccine for both VACV-naïve and non-naïve people (134, 252, 253). 
However, the serious adverse effects of VACV vaccination prevent the widespread use 
of a VACV-based vaccine in a civilian population without an outbreak. Furthermore, 
the vaccine is contraindicated in up to 30% or more of the population, including 
infants, pregnant women or women who are breastfeeding infants, the 
immunocompromised, those with eczema or exfoliative skin disorders, people who 
live in the same house or are in intimate contact with people with the above 
conditions, and people with cardiovascular conditions (such as a history of myocardial 
infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient 
ischaemic attack, chest pain or shortness of breath with activity, or any cardiac 
condition under the care of a physician) (US Centers for Disease Control and 
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Prevention, ww.bt.cdc.gov/agent/smallpox/vaccination/contraindications-clinic.asp; 
(251, 254)).  
A third-generation vaccine based on modified vaccinia virus Ankara (MVA), a highly 
attenuated replication-deficient strain of VACV, is currently being tested (89, 243, 
255, 256). MVA was attenuated by Mayr et al. towards the end of the campaign for the 
eradication of smallpox in 1975 by more than 570 passages of the VACV strain 
chorioallantois vaccinia virus Ankara (CVA) in chicken embryo fibroblasts (CEF) 
(257). Thereby, MVA has lost about 15% of the CVA genome (ca. 30 kb) including 
several host-range genes and with it the ability to replicate efficiently in primate cells; 
limited replication has been demonstrated in certain mammalian cell lines, like BHK 
and BS-C-1 cells  (258-262). The 193 ORFs mapped in the MVA genome (178 kb) 
probably correspond to 177 genes, 25 of which are split and/or have suffered 
mutations resulting in truncated proteins particularly affecting the host interactive 
proteins, but also involving some structural proteins. MVA no longer encodes many of 
the soluble inhibitors of cytokine and chemokine function as well as other factors that 
play a role in immune evasion. Its safety and its ability to protect against the 
development of poxvirus infections in several animal models has been demonstrated 
(263-265). MVA was used in almost 120,000 Caucasian individuals with no reported 
side effects, although many of the subjects were among the population with high risk 
of developing complications (263).  
1.2.3.2  Modified vaccinia virus Ankara as viral vector 
Viruses are natural gene delivery systems inducing immune responses and have been 
developed as such (for review see (266)). Several features have made poxviruses highly 
attractive for use as viral antigen delivery systems: the capacity to stably carry up to 25 
kb of recombinant DNA (267), precise virus-specific control of target gene expression, 
lack of persistence or genomic integration in the host, wide tropism, high 
immunogenicity as vaccine, no yet identified interference mechanisms with host cell 
antigen processing or presentation, and ease of vector and vaccine production (268-
270). Even if there might exist low preexisting anti-vector immunity in formerly 
vaccinated individuals (245), this appears to be a less significant problem (271). 
In 1982, it was first shown that genes coding for immunogenic proteins can be 
inserted into VACV DNA without impairing the ability of the virus to grow in tissue 
culture (272). Animals infected with these recombinant VACV containing genes 
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coding for a variety of immunizing proteins were protected against challenge infection 
with the corresponding infectious agent (Hepatitis B virus (273), rabies (274), malaria 
(275)).  
Concerns about the safety of VACV as viral vector have been addressed by the 
development of non-replicating vectors (268, 276), such as MVA (see chapter  1.2.3.1, 
(269-271)), other highly attenuated strains of VACV (e.g. NYVAC, a derivative of 
VACV strain Copenhagen, from which 18 ORFs were specifically deleted (277)) and 
avipoxvirus vectors being replication-competent only in avian tissue (278). 
Because of their well-established safety (see chapter 1.2.3.1, (263)), recombinant MVA 
are today among the most promising live viral vector systems for humans, capable of 
evoking potent cellular and humoral immune responses against their insert 
immunogens, especially when used in a DNA-prime / virus-boost immunization 
schedule (270, 279, 280). Despite its limited replication, MVA provides similar levels 
of recombinant gene expression as replication-competent VACV in human cells (269), 
and levels of antibody and T cell responses, and protection proved to be at least equal 
to that induced by recombinant VACV in the same systems. The enhanced 
immunogenicity of recombinant MVA may largely be attributed to the deletion of 
certain immune evasion genes (258, 259). 
Numerous phase I/II clinical trials with recombinant MVA as vaccine against 
infectious diseases, such as HIV, malaria, or tuberculosis, and tumors have been 
performed or are under way (95, 279-288).  
1.2.3.3  Orthopoxviruses as oncolytic viruses 
Oncolytic virotherapy is an emerging biotherapeutic platform based on genetic 
engineering of viruses capable of selectively infecting and replicating within cancer 
cells (289-291). Although VACV shows no specific preference to bind and infect 
transformed cells, several studies have shown increased viral replication levels in 
tumors (292), and a VACV strain with deletions of the genes that encode thymidine 
kinase and the vaccinia growth factor showed preferential replication in rapidly 
growing tumor cells while becoming attenuated for overall virulence (293, 294). 
VACV has many of the features thought necessary for an effective oncolytic virus: a 
short life cycle, rapid spread, strong lytic ability, well-defined molecular biology (295). 
The ability to insert multiple genes into poxviruses in order to increase their 
therapeutic potential or to assist in the virus’ visualization is further a great advantage 
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of poxvirus-based vectors (292, 296). Importantly, a broad spectrum of clinical 
experience has been obtained with VACV. The virus produces no known disease in 
humans, and has already demonstrated anti-tumor efficacy in trials with vaccine 
strains (295).  
Although attempts have been made to target VACV binding to specific cell types by 
engineering virion surface proteins that mediate host cell binding (297), such attempts 
have never circumvented the ability of the virus to bind to and enter mammalian cells 
promiscuously. It is likely that future use of oncolytic poxviruses will involve 
exploiting the signaling differences between normal and transformed cells so that the 
oncolytic virus will spread efficiently in tumor cells, as well as deliver therapeutic 
transgenes to assist in tumor killing and immunotherapy (215, 297, 298).  
Other poxviruses have also been tested as oncolytic viruses, for example, myxoma 
virus, which is normally restricted to non-human cells, but replicates nevertheless 
robustly in human tumor cells (299, 300). 
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1.3 Aims of thesis 
Viral and phosphorylated HLA ligands are difficult to identify in the multitude of self- 
and non-phosphorylated HLA ligands, respectively. Low abundancy of these special 
peptides compared to other ligands may be a further complication. Both subsets of 
peptides require additional strategies for their identification. The aim of this thesis was 
to establish techniques which enable the specific analysis of the two HLA ligand 
repertoires, viral HLA class I ligands (Part I) and phosphorylated HLA class I and II 
ligands (Part II), and which avoid analysis of the complete HLA ligand repertoire of 
cells. 
 
Questions to be answered by this thesis were: 
 
Part I:  
- Which HLA class I ligands are presented by MVA-infected cells? 
- Are these ligands immunogenic? Do they provide protection against viral 
infection? 
- Is there a correlation between presentation of viral HLA ligands and the steady 
state amount of viral intracellular protein? 
- Does MVA-infection induce presentation of individual human self-HLA 
ligands? 
 
Part II: 
- Which phosphorylated HLA ligands are presented by tumor tissue (renal cell 
carcinoma)? Are the phosphorylations contained in these ligands described to 
be associated with malignant cellular processes? 
- Does the tumor present phospholigands which are lacking on corresponding 
healthy renal tissue? 
- Are phosphorylated peptides presented by HLA class II? 
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2 Materials and Methods 
 
TFA, acetonitrile, formic acid, HPLC water, DMSO, and β-mercaptoethanol were 
from Merck (Darmstadt, Germany). 
2.1 Materials and Methods of Part I 
2.1.1 Cell lines and antibodies  
The human B lymphoblastoid cell line (B-LCL) JY expressing HLA-A*0201 and 
B*0702, (ECACC Cat.no. 94022533) and the human HLA-A*0201 transfected CML cell 
line K562/A*0201 (301) were used as described (113) and maintained in RPMI 1640 
(C.C.Pro, Neustadt, Germany) containing 10% FCS (Pan Biotech, Aidenbach, 
Germany) and supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin (Bio Whittaker, Verviers, Belgium). 
IgG2a antibodies B1.23.2 (anti-HLA-B, C) (302) and W6/32 (anti-HLA-A, B, C) (303) 
were purified from hybridoma supernatants using protein A Sepharose beads (GE 
Healthcare, Uppsala, Sweden). 
2.1.2 Virus  
MVA was routinely propagated and titrated following standard methodology as 
described (304) by Wolfgang Kastenmüller (Institute of Virology, Technical University 
Munich and Helmholtz Center Munich).  
For infection with MVA, 1.4 x 1010 JY cells were incubated at 2.8 x 1010 cells/l with 
MVA to obtain a multiplicity of infection of 7. After 2 h, infected cell suspensions 
were diluted to 5.2 x 109 cells/l and maintained for 10.5 h at 37°C. 
2.1.3 Donors  
Donors 1 and 2 (HLA-A*0201 positive) were immunized twice with MVA in an 
interval of 30 d. Blood was taken as indicated in Figure 3.4. This was done by Ingo 
Drexler (Institute of Virology, Technical University Munich and Helmholtz Center 
Munich). Dryvax® vaccinees were HLA-A*0201 positive and blood samples were taken 
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25 y, 29 y, and 44 y post vaccination for donors 3, 4, and 5, respectively. PBMC were 
isolated using Ficoll density centrifugation (Lymphocyte Separation Medium, PAA 
Laboratories, Pasching, Austria). This study was approved by the Ethics committees of 
the University of Tubingen and of the Technical University Munich. 
2.1.4 Isolation of HLA class I ligands 
HLA ligands were obtained by immunoprecipitation of HLA molecules from 1.4 x 1010 
cells of MVA- and mock-infected JY using a slightly modified protocol (305) that 
involves the antibodies B1.23.2 and W6/32 coupled to CNBr-activated sepharose 
(Roche, Mannheim, Germany) followed by acidic elution and size exclusion 
ultrafiltration. To separate HLA-A and -B ligands affinity chromatography based on 
two distinct columns was performed: the first column was loaded with B1.23.2 (an 
antibody binding to HLA-B/C) and the second one with antibody W6/32 (binding to 
HLA-A/B/C). Therefore, HLA-B*0702 bound to B1.23.2 first whereas HLA-A*0201 
bound to W6/32 and ligands from both HLA molecules were eluted separately. 
2.1.5 Peptide modification and analysis  
Modification of peptides was carried out as described (306). In brief, lysine side chains 
of peptides were blocked by O-methyl isourea hemisulfate (Acros Organics, Geel, 
Belgium). Peptides were desalted using Peptide Cleanup C18 Spin Tubes (Agilent, Palo 
Alto, CA, USA) and subsequently nicotinylated on the column for 15 min at room 
temperature using a 20 mM light (H4) or heavy (deuterated, D4) 1-([1H4/2D4] 
nicotinoyloxy)succinimide solution in 50 mM phosphate buffer pH 8.5. After 
aminolysis of undesirable nicotinylated tyrosine esters, peptides were eluted by 50 μl 
of 50% acetonitrile, 1% formic acid.  
Peptide analysis was carried out as described (307) using an Ultimate HPLC system 
(Dionex, Amsterdam, Netherlands) with a gradient ranging from 15 to 55% solvent B 
within 170 min. The mix of the peptide samples from MVA- and mock-infected JY 
cells was recorded in an LC-MS experiment without fragmentation using a hybrid 
quadrupol orthogonal acceleration time of flight mass spectrometer (Q-TOF I, 
Micromass, Manchester, UK), equipped with a micro-electrospray ionization source, as 
described (305, 307). For peptide sequence analysis the sample derived from MVA-
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infected cells was analyzed in a separate LC-MS/MS experiment. Fragment spectra 
were evaluated manually and database searches (NCBI, Expressed Sequence Tag) were 
carried out using the MASCOT search engine (www.matrixscience.com) (308). All 
viral HLA ligand sequences are available at www.syfpeithi.de. 
2.1.6 Peptides  
HLA-A*0201 restricted peptides derived from MVA proteins (Table I), HCMV pp65495-
503 (NLVPMVATV), EBV BMLF1259-267 (GLCTLVAML), Influenza virus M158-66 
(GILGFVFTL) and HIV-1 RT476-484 (ILKEPVHGV) were synthesized by standard Fmoc 
chemistry using an Economy Peptide Synthesizer EPS 221 (ABIMED, Langen, 
Germany). Purity of peptides was analyzed by HPLC (Varian Star; Zinsser Analytics, 
Munich, Germany) and identity confirmed by MALDI-MS (GSG future; GSG, 
Bruchsal, Germany). This was done by Patricia Hrstić (Department of Immunology, 
Institute of Cell Biology, University of Tübingen). MVA synthetic peptides were 
further measured by LC-MS/MS (modified as described above) and fragmentation 
spectra were compared to the spectra obtained from endogenous MVA peptides. For T 
cell experiments all peptides were dissolved in 10% DMSO at 1 mg/ml.  
2.1.7 Recombinant HLA molecules and fluorescent tetramers  
Biotinylated recombinant HLA class I molecules and fluorescent HLA tetramers for 
CD8+ T cell analysis were produced as described (309). Briefly, fluorescent tetramers 
were generated by co-incubating biotinylated HLA-A*0201 monomers with PE- or 
Allophycocyanin-conjugated streptavidin (Molecular Probes, Leiden, The 
Netherlands) at a 4:1 molar ratio. 
2.1.8 In vitro sensitization of human CD8+ T cells using synthetic 
peptides  
PBMC were cultured in IMDM (Bio Whittaker, Verviers, Belgium) containing 10% 
heat-inactivated human serum (PAA) and 50 μM β-mercaptoethanol (Merck, 
Darmstadt, Germany). IL-4 and IL-7 (5 ng/ml; R&D Systems, Wiesbaden, Germany) 
were added after thawing PBMC in DNase (3 μg/ml; Sigma-Aldrich) containing 
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medium and washing them once in medium without DNase. On d1 peptides (1 μg/ml) 
prepared as mixtures of five peptides each were added to PBMC: mix 1: F12L404-412, 
G5.5R27-35, B19R207-215, A23R273-281, B8R18-27; mix 2: C7L74-82, A48R187-195, B22R79-87, H3L184-
192, A47L155-163; mix 3: O1L247-255, E5R93-101, D12L62-70, D12L251-259, B22R178-186; mix 4: 
O1L335-344, J6R303-311, B15R91-101) and IL-4 and IL-7 (5 ng/ml) were added. On d3, d5 and 
d7, IL-2 (2 ng/ml, R&D Systems) was added. Medium was exchanged after d9 when 
necessary. On d12, part of the cells were used for IFN-γ ELSPOT assay. The remaining 
cells were restimulated by addition of peptide (1 μg/ml), followed by IL-2 (2 ng/ml) 24 
h later and analysis by combined tetramer / intracellular IFN-γ staining on d20. 
2.1.9 IFN-γ ELISPOT assay  
IFN-γ ELISPOT was performed essentially as described (113) except 5 x 105 
PBMC/well were seeded in coated 96-well nitrocellulose plates (MSHAN4B50, 
Millipore, Bedford, MA) and 5 x 104 K562/A*0201 cells/well and 1 μg/ml peptide were 
added. An HLA-A*0201 restricted HIV-peptide was used as negative control; positive 
control wells contained PHA (Roche). After 26 h at 37°C cells were transferred into a 
96 well plate and maintained for further investigation. Remaining cells were removed 
by washing once with PBS/0.05% Tween 20 (Serva, Heidelberg, Germany), once with 
sterile water and five times with PBS Tween. Captured IFN-γ was detected by 
incubation for 2 h at room temperature with biotinylated mAb anti-hIFN-γ (7-B6-1, 
0.33 μg/ml; Mabtech, Nacka Strand, Sweden) in PBS 0.5% BSA (Sigma-Aldrich). After 
washing with PBS Tween the plates were incubated with ExtrAvidin 
Alkalinphosphatase (1:100; Sigma-Aldrich) for 1 h at room temperature. Unbound 
complex was removed by washing. Peroxidase staining was performed with BCIP/NBT 
(5-bromo-4-chloro-3-indolylphosphate toluidine and nitroblue tetrazolium; B5655, 
disolved in water; Sigma-Aldrich) for 7 min. Spot numbers were automatically 
determined (Immunospot Image Analyzer, series 1; ImmunoSpot Software Version 
3.2e; both Cellular Technology, Cleveland, OH). To calculate the number of cells 
responding to a particular peptide, the mean spot numbers induced by the control 
peptide were subtracted from mean spot numbers induced by MVA peptides.  
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2.1.10 Tetramer staining  
1 day after ELISPOT analysis the transferred cells were stained by tetramers (in each 
case using a tetramer containing a peptide other than the peptide used for stimulation 
in ELISPOT analysis) using PE-tetramers for MVA peptides, Allophycocyanin-
tetramers for control peptides, anti-CD8-PE Cy7 and anti-CD4-FITC (BD Biosciences, 
Heidelberg, Germany). Cells were incubated 30 min with fluorescent HLA-A*0201 
tetramers, followed by 20 min incubation with the antibodies in the dark at 4°C. After 
resuspending with PBS containing 1% paraformaldehyde, 2% FCS (inactivated at 56°C 
for 30 min; Pan, Aidenbach, Germany), 2 mM EDTA and 0.01% sodium azide cells 
were analyzed on a FACSCalibur cytometer (BD Biosciences). 
2.1.11 Combined tetramer / intracellular IFN-γ staining  
After two rounds of peptide/IL-2 in vitro sensitization PBMC were washed in IMDM, 
resuspended at 2 x 107 cells/ml, and cultured for 7 h in IMDM containing either one of 
the MVA peptides or a control HLA-A*0201 restricted HIV peptide (10 μg/ml) and 
Golgi-Stop solution (BD Biosciences). Stimulation with PMA/Ionomycin was used as 
positive control. Cells were stained using the PE-tetramers mentioned above, anti-
CD8-PE Cy7, the Cytofix/Cytoperm Plus kit for permeabilization and anti-IFN-γ-FITC 
(BD Biosciences). Cells were analyzed on a FACSCalibur cytometer (BD Biosciences). 
2.1.12 Proteomic analysis 
At 12.5 h post infection JY cells were used for analysis of intracellular proteins as 
described (310) with slight modifications. Approximately 200 μg of intracellular 
proteins extracted from MVA- and mock-infected cells were separated by 2D-PAGE 
(first dimension: pH 3-10NL, 24 cm (Biorad, Hercules, USA), 70 kVh; second 
dimension: 12% SDS-PAGE). Gels were stained by Flamingo fluorescent staining 
(BioRad) and scanned  using a  laser scanner (FLA 5100, Fujifilm, Tokyo, Japan) and by 
silver staining as described (311) and scanned on a flatbed scanner (Powerlook 2100 
XL, UMAX, Willich, Germany). Protein preparations from two infection experiments 
were subjected to 2D-PAGE in duplicates. All eight gels were comparatively evaluated 
using differential image analysis software (Progenesis SameSpots, Nonlinear Dynamics, 
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Newcastle upon Tyne, UK). All spots representing proteins which were unique or 
overexpressed upon MVA infection were excised manually from the gels, digested 
with trypsin, and peptide fragments were analyzed by LC-MS/MS as described (310). 
Significant overexpression was defined for spots detected >1.6-fold higher upon MVA 
infection and an ANOVA value of <0.05 comparing the gels of both conditions. Even 
though the majority of analyzed proteins was overexpressed in both experiments, 
differential spots detectable on gels of only one of the two experiments were also 
analyzed. Peptide sequences were identified using the MOWSE algorithm as 
implemented in the MASCOT software (Matrix Science, London, UK) (308) and using 
the NCBI database (as of 30/04/2007) containing human and MVA protein sequences. 
The proteomic analysis was done by Mirita Franz-Wachtel, Inga Buchen, Johannes 
Madlung, Claudia Fladerer, and Tobias Lamkemeyer (Institute of Cell Biology, 
Proteome Center Tübingen, University of Tübingen). 
2.1.13 Vaccination of HLA-A*0201-transgenic mice against a 
lethal challenge with VACV strain Western Reserve (VACV 
WR) 
For peptide vaccination, HLA-A*0201 transgenic HHD+/+ ß2m-/- Db-/- HHD II mice (95) 
were immunized subcutaneously with pools of synthetic peptides (0.03 mg/peptide; 
Biosynthan, Berlin, Germany) and synthetic CpG-ODN 1668 (10 nMol; TIB-Molbiol, 
Berlin, Germany). 
Quantification of antigen-specific CD8+ T cell responses. PBMC isolated on d7 from 
vaccinated mice were stimulated with peptide pools (Early/Late pep) or a control 
peptide (Control pep) for 5 h. HLA-A*0201 restricted control peptides were Tyr369-377 
(derived from human tyrosinase), FluM58-66 (derived from the A/PR/8/34 Influenza 
virus matrix protein M1) and pp65495-503 (derived from the human cytomegalovirus 
internal matrix protein pp65). Brefeldin A (1 mg/ml; Sigma-Aldrich) was added for the 
last 3 h. Cells were live/dead stained with ethidium monoazide bromide (Molecular 
Probes, Leiden, the Netherlands) and blocked with anti-CD16/CD32-Fc-Block (BD 
Biosciences). Surface markers were stained with Allophycocyanin-conjugated anti-
CD8 and anti-CD62L-PE (Caltag, now Invitrogen, Carlsbad, USA). Intracellular IFN-γ 
staining was performed with anti-IFN-γ-FITC (clone XMG1.2) using the 
Cytofix/Cytoperm kit for permeabilization (BD Biosciences Pharmingen). Data were 
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acquired by FACS analysis on a FACSCanto (BD Biosciences) and were analyzed with 
FlowJo (Tree Star, Ashland, USA) software.  
Protection assays. 8 days after immunization with virus or after peptide immunization 
(see A), mice were infected intranasally with VACV WR (originally provided by 
Bernard Moss (NIH, Bethesda, USA)) diluted in 30 μl PBS, and monitored for more 
than 3 weeks with daily measurement of individual body weights as described 
previously (95). Mice suffering from severe systemic infection and having lost >30% of 
body weight were sacrificed. The mean change in body weight was calculated as 
percentage of the mean weight for each group on the day of challenge. This 
experiment was performed by Georg Gasteiger, Wolfgang Kastenmüller, Anya Krefft, 
and Ingo Drexler (Institute of Virology, Technical University Munich and Helmholtz 
Center Munich). 
2.2 Materials and Methods of Part II 
2.2.1 Tissues and cell lines 
Renal cell carcinoma tissue (RCC414) (classified T1bNxM1) and surrounding healthy 
renal tissue were excised from a patient (HLA-A*02, -A*24, -B*07, -B*35) at the 
University clinic Tubingen by Jörg Hennenlotter and stored as described (305). This 
study was approved by the Ethics committees of the University of Tubingen.  
The human B lymphoblastoid cell line (B-LCL) JY (ECACC Cat.no. 94022533; HLA-
DRB1*04, -DRB1*13) and the human melanoma cell line MaMel-8a (European 
searchable Tumour Line Database ESTDAB-105; expressing HLA-DRB1*01) were 
maintained in RPMI 1640 (C.C.Pro, Neustadt, Germany) containing 10% FCS (Pan 
Biotech, Aidenbach, Germany). 
Monoclonal IgG2a antibodies W6/32 (anti-HLA-A, B, C) (303) and L243 (anti-HLA-
DR) (312) were purified from hybridoma supernatants using protein A Sepharose 
beads (GE Healthcare, Uppsala, Sweden). 
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2.2.2 Peptides 
Peptides were synthesized by standard Fmoc chemistry using an Economy Peptide 
Synthesizer EPS 221 (ABIMED, Langen, Germany). Purity of peptides was analyzed by 
HPLC and identity confirmed by MS. This was done by Patricia Hrstić. 
2.2.3 Isolation of MHC ligands and stable isotope labeling 
MHC ligands were obtained by immunoprecipitation of MHC molecules from 
approximately 2 x 1010 cells  (JY, MaMel-8a) or from RCC and healthy renal tissue 
using a slightly modified protocol (305) that involves the antibodies B1.23.2 and 
W6/32 coupled to CNBr-activated sepharose (Roche, Mannheim, Germany) followed 
by acidic elution and size exclusion ultrafiltration. Phosphatase inhibitor cocktails 1 
and 2 (Sigma-Aldrich, St. Louis, MO, USA) were added to the lysate of JY cells. 
Modification of peptides was carried out as described (306). Isolation of MHC ligands 
from RCC and healthy renal tissue was done by Anneke Neumann. 
2.2.4 Phosphopeptide enrichment 
Samples of modified peptides were taken to dryness and resolved in 40 μl of loading 
buffer (50% acetonitrile/water, 6% trifluoric acid, pH<1). TiO2 (Titansphere 5 micron, 
loose media, GL Sciences, Tokyo, Japan; GELoader Tips, Eppendorf, Hamburg, 
Germany) microcolumns were packed as described (207). For centrifugation in a 
microcentrifuge, TiO2-microcolumns were inserted into a cut tip (epT.I.P.S. 2-200 
μL, 53 mm, Eppendorf), a bottom-cut 0.5 ml tube and a 1.5 ml tube (Safe-Lock micro 
test tubes, Eppendorf) (see Figure 4.1). Columns were sequentially loaded with 
solutions using GELoader tips (Eppendorf) and centrifuged in the tip-holding tubes 
(Figure 4.1) at 10,000 rpm (MHC class I peptides) or 11,000 rpm (MHC class II 
ppeitdes) in a conventional tabletop microcentrifuge without letting the TiO2 run dry. 
Centrifugation times depended on the amount of peptides contained in the sample 
(approximately 20 s for 10 μl, 30 s for 20 μl and 50 s for 40 μl for MHC class I peptides 
at 10,000 rpm; for MHC class II peptides centrifuagtion times were about three times 
as long at 11,000 rpm). Solutions used for enrichment were essentially as described 
(207, 313). Columns were equilibrated three times with 20 μl loading buffer and the 
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sample was loaded on the column three times. The column was washed twice with 20 
μl of loading buffer, and twice with 10 μl of water. The flowthrough of the sample was 
pooled with the flowthrough of washing solutions for analysis of unbound peptides. 
Column-bound peptides were eluted by 5 times 10 μl and once 30 μl of elution buffer 
(1% ammonia, 20% acetonitrile, pH∼11). The eluate was taken to dryness and resolved 
in solvent A for LC-MS/MS analysis. 
2.2.5 Peptide analysis  
Peptide analysis was carried out as described (307) using a reversed phase HPLC 
system (CapLC, Waters, Manchester, UK; C18-column PepMap 75 μm x 25 cm 
(Dionex LC Packings, Sunnyvale, CA, USA); solvents: A: 4 mM ammonium acetate 
adjusted to pH 3.0 by formic acid, B: 80% acetonitrile/water and 2mM ammonium 
acetate adjusted to pH 3.0 by formic acid) with a gradient ranging from 10 to 50% 
solvent B within 90 min. LC-MS/MS- and LC-MS-analyses were performed using a Q-
TOF Ultima (Waters) equipped with an ESI source as described (305, 307). Fragment 
spectra were evaluated manually and database searches (NCBI, Expressed Sequence 
Tag) were carried out using the MASCOT search engine (www.matrixscience.com) 
(308). Identity of several endogenous peptides was confirmed by synthetic peptides.  
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3 Results and Discussion Part I  
3.1 Long-term immunity against actual poxviral HLA ligands as 
identified by differential stable isotope labeling  
This chapter (except Figure 3.3) was submitted by the authors below and has been 
accepted by the Journal of Immunology on August 27, 2008 for publication. 
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3.1.1 Abstract 
Viral peptides are presented by HLA class I on infected cells to activate CD8+ T cells. 
Several immunogenic peptides have been identified indirectly by epitope prediction 
and screening of T cell responses to poxviral vectors including modified vaccinia virus 
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Ankara (MVA) currently being tested as recombinant or smallpox vaccines. However, 
for the development of optimal vaccination and immunomonitoring strategies it is 
essential to characterize the actual viral HLA ligand repertoire of infected cells. We 
used an innovative approach to identify naturally processed MVA HLA ligands by 
differential HPLC-coupled mass spectrometry. We describe twelve viral peptides 
presented by HLA-A*0201 and three by HLA-B*0702. All HLA-A*0201 ligands 
participated in the memory response of MVA-immune donors and several were 
immunogenic in Dryvax® vaccinees. Eight epitopes were novel. Viral HLA ligand 
presentation and viral protein abundance did not correlate. All ligands were expressed 
early during the viral life cycle and a pool of three of these mediated stronger 
protection against a lethal challenge in mice as compared to late epitopes. This 
highlights the reliability of the comparative mass spectrometry-based technique to 
identify relevant viral CD8+ T cell epitopes for optimizing the monitoring of protective 
immune responses and the development of effective peptide-based vaccines. 
3.1.2 Introduction 
Viruses are one of the main factors which modify the repertoire of HLA ligands, the 
peptides associated with human MHC molecules. Viral HLA ligands are presented to T 
cells carrying the appropriate TCR in order to elicit a specific cellular immune 
response, thus making infected cells visible to the immune system. T cell responses 
were shown to play an essential role in clearance of poxvirus infections (238, 254, 
314). Smallpox disease, caused by variola virus (VARV), was eradicated in the 1970s by 
vaccination with cross-protective vaccinia virus (VACV, Dryvax®) (237). Although, in 
general, vaccinations aim to induce a strong antibody response to achieve viral 
clearance, vaccinees with T cell defects failed to control the infection after 
immunization (238, 254). 
Despite the eradication of smallpox, there are several reasons for studying the cellular 
immune response to VACV. First, there is a constant threat that VARV may be 
reintroduced by acts of bioterrorism or that forms of new pathogenic poxviruses may 
evolve from, for example, zoonotic human monkeypox virus (MPXV) (243, 249). Since 
smallpox vaccination was stopped in the late 1980s, a large part of the population is 
unprotected. Dryvax®, the only currently licensed vaccine against smallpox, carries 
the highest rate of side effects of any approved vaccine. Therefore, modified vaccinia 
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virus Ankara (MVA), an attenuated replication-deficient strain of VACV, is currently 
being tested as a safer third-generation vaccine (89, 243, 255, 256). A more detailed 
understanding of the CTL response to MVA allows both the development of epitope-
based vaccines promising a safe, stable and handy alternative to traditional vaccination 
strategies, as well as the monitoring of clinical trials by following MVA-specific T cell 
responses (93, 315). Furthermore, MVA has been successfully introduced as a highly 
immunogenic recombinant viral vector vaccine for immunotherapy of infectious 
diseases and cancer (270), which requires the assessment of T cell epitope-specific 
responses elicited against vector and recombinant antigens. 
Several CD8+ T cell epitopes of MVA and other VACV strains have been identified by 
indirect approaches applying epitope prediction (e.g. using www.syfpeithi.de) and 
subsequent T cell screening of immune donors, both human (95-104) and mouse (79, 
105-108). Despite the increasing number of epitopes published, there is an ongoing 
need for further investigation. First, although thousands of peptides have been 
screened, covering approximately 35% of the large viral DNA genome which encodes 
more than 200 non-overlapping open reading frames (ORF), the published 
determinants represent only a fraction of the total anti-viral CTL response (93). 
Second, only a small number of the identified epitopes have been validated so far (93). 
Third, our recent work challenges the indirect strategy to identify epitopes which is 
based on the monitoring of T cell responses alone: upon a first vaccination with MVA, 
T cells were primed against viral peptides that were not necessarily presented by 
infected cells but cross-presented by non-infected cells (316). During a second 
infection, however, only T cells with the ability to recognize viral peptides that were 
efficiently presented on infected cells participated in the recall response and mediated 
survival (112). Therefore, the identification of the viral HLA ligands which are 
actually presented on infected cells appears crucial for the design and monitoring of 
protective prophylactic vaccines. 
Thus, we set out to identify peptide ligands presented on HLA class I of virus-infected 
cells by mass spectrometry (MS). MS allows the identification of the exact chemical 
composition of T cell epitopes, including those generated by posttranslational 
modifications. Thus, directly sequenced HLA ligands have been considered to be more 
reliable than determinants identified solely by T cell analysis (155), which is 
mandatory to accurately determine the magnitude of specific CD8+ T cell responses or 
the functionality of the CD8+ T cells that respond to an epitope. So far, only one MVA-
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derived HLA ligand has been identified by mass spectrometry, however, without 
demonstrating immunogenicity (134). Ideally, immunologically relevant viral T cell 
epitopes are confirmed both as HLA ligands and as T cell stimulators. 
The challenge in MS-based discovery of viral HLA ligands is to pinpoint the signals 
derived from viral sequences among the hundreds of signals produced by human self-
peptides. In the past, nanoHPLC-coupled tandem MS analyses (LC-MS/MS) performed 
with chemically synthesized predicted epitopes and endogenously processed peptides 
isolated from virus infected cells were compared in order to reveal the presence of the 
predicted epitope (131). In order to systemically search for viral HLA ligands, two 
strategies relying on the comparison of HLA ligands from virus-infected and non-
infected cells have been applied. First, in silico subtraction of the two respective 
nanoHPLC-coupled MS analyses (LC-MS) (132), and second, metabolic stable isotope 
labeling of HLA ligands prior to purification (133, 135).  
Here, we describe a novel approach to identify viral HLA ligands by differential stable 
isotope labeling of HLA ligands purified from MVA infected and mock-infected cells. 
This strategy is based on a technique recently established in our laboratory (307) to 
compare the repertoires of HLA ligands of tumor and healthy tissue (306, 317). We 
found 15 viral peptides of which twelve were presented by HLA-A*0201 and three by 
HLA-B*0702. Nine peptides have not been described as CTL epitopes so far. All HLA-
A*0201 ligands were actual memory CTL epitopes in MVA vaccinees. Eight of these 
epitopes were novel. All ligands were expressed early during the viral life cycle, 
although late protein synthesis was not impaired. Importantly, early viral HLA ligands 
mediated protection against a lethal respiratory challenge in mice while late viral 
peptides previously described as CTL epitopes were inefficient. 
3.1.3 Results 
3.1.3.1  Identification of 15 MVA-derived HLA-A*0201 and HLA-B*0702 
ligands 
In order to identify MVA-derived HLA ligands presented by HLA-A*0201 and B*0702, 
we differentially analyzed the ligands isolated from MVA- and mock-infected cells of 
the human B-LCL JY after 12.5 h of infection. Figure 3.1 schematically illustrates the 
further experimental procedure. HLA-presented peptides were chemically modified 
by covalently-linked stable isotope tags: peptides isolated from MVA-infected cells 
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with heavy (deuterated, D4) nicotinic acid (NIC) and peptides isolated from mock-
infected cells with light (hydrogenated, H4) NIC. The two pools of tagged peptides 
were mixed, and the peptides were separated by nanoHPLC and analyzed online by 
MS. HLA ligands present on both MVA- and mock-infected cells were detected as 
doublets with a mass difference of 4 Da, due to the four deuterium atoms of D4NIC 
(Figure 3.1, lower central panel) replacing four hydrogen atoms present in H4NIC. In 
contrast, viral HLA ligands presented only by infected cells appeared as single peaks 
(Figure 3.1, upper central panel; Figure 3.2). The peptides corresponding to single 
peaks were then sequenced by fragmentation using LC-MS/MS analysis (Figure 3.1, 
right panel; Figure 3.2). All viral peptides identified were synthesized chemically and 
analyzed by the same procedure to verify their sequences (Figure 3.2; data not shown).  
We discovered twelve viral HLA ligands among the peptides isolated from HLA-
A*0201 (Table 3.1). Seven of these were novel (Figure 3.2), while four had previously 
been published as CTL determinants (see Table 3.6 for references), and one peptide 
(A48R187-195: IVIEAIHTV) had been described before as an MVA-derived HLA-A*0201 
ligand identified by LC-MS/MS (134), but had not been confirmed as CTL epitope. In 
addition, we detected three viral HLA ligands among the peptides isolated from HLA-
B*0702 (Table 3.1), one of which was also novel (Figure 3.2).  
In total, we confirmed six established CTL epitopes as well as one MVA-derived HLA 
ligand, and additionally found eight novel ligands which represent potential CTL 
epitopes. All twelve viral HLA ligands were detected within an intensity range of one 
order of magnitude, suggesting an absolute quantity of about 150-1500 specific 
peptide/MHC-complexes per cell. This is in line with the absolute quantity of viral 
HLA ligands published for other viruses ((12), reviewed in (130)). Peptides presented 
at lower levels may be missed by this approach. 
The lower number of viral peptides identified for HLA-B*0702 in comparison to HLA-
A*0201 reflects the more stringent HLA-B*0702 peptide motif, which requires the 
relatively infrequent proline residue in position 2 within its ligands 
(www.syfpeithi.de). The HLA-A*0201 motif, in contrast, is less restrictive, with 
frequent amino acids as anchors in position 2 (leucine, methionine, valine, isoleucine) 
and 9 (valine, leucine, isoleucine, alanine). 
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Figure 3.1 Strategy of differential MS-based HLA ligand analysis. HLA ligands were purified 
from extracts of MVA-infected (right) and mock-infected (left) cells. Peptide ligands were 
labeled differentially by chemical modification of the N-terminus with light isotopes (mock-
infected, 105 Da, H4NIC) and heavy isotopes (MVA-infected, 109 Da, D4NIC) of nicotinic acid, 
giving respective peptides a difference in mass to charge ratio (Δm/z) of 2 Da (z = 2). LC-MS 
analysis of a mix of both pools revealed the quantity of a peptide in the MVA-infected sample 
relative to the quantity in the mock-infected sample (double peak with Δm/z = 2, lower central 
panel; isotopic peaks appear in m/z = 0.5 Da intervals). HLA ligands potentially derived from 
MVA proteins are present in only one pool and are found as single peaks (upper central panel). 
The right panel representatively depicts the sequencing of a peptide of interest by separate LC-
MS/MS-analysis, which generates fragmentation spectra. Identification of other newly identified 
MVA peptide sequences is shown in Figure 3.2. 
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Figure 3.2 Identification of MVA HLA ligands by LC-MS and LC-MS/MS. syn. = synthetic 
peptide; z = 2 in LC-MS data, z = 1 in LC-MS/MS data; Gua = guanylated (as described in (307), 
reactivity of lysine side chains was blocked by chemical reaction with O-methyl isourea 
hemisulfate before nicotinylation (D4NIC) of peptide N-termini) 
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Table 3.1   MVA-derived HLA ligands identified by differential MS analysis of MVA- and mock-
infected B-LCL 
      
Sequence ORFa Epitope 
locationb 
Proteina Locus 
tagc 
Temporal 
expressiona 
      
HLA-A*0201:      
      
KLIIHNPELd B19Re 207-215 (234) IFN-α/β-receptor-like secreted glycoprotein 187 early 
KLFSDISAI E5R 93-101 (317) abundant component of the virosome 052 early 
SLKDVLVSV G5.5R 27-35 (63) DNA-dependent RNA polymerase subunit rpo7 075 early 
TLLDHIRTA B22R, 
C16Lf 
178-186 (188) hypothetical proteinf 189, 
004.5 
early 
ALDEKLFLI A23R 273-281 (382) intermediate gene transcription factor VITF-3 
45kDa large subunit 
134 early/late 
KITSYKFESV B8R 18-27 (226) soluble interferon-gamma receptor-like 176 early/late 
IVIEAIHTV A48R 187-195 (204) thymidylate kinase 161 early/late 
KLFTHDIML D12L 62-70 (287) mRNA capping enzyme small subunit 109 early/late 
RVYEALYYV D12L 251-259 (287) mRNA capping enzyme small subunit 109 early/late 
KVDDTFYYV C7L 74-82 (150) possible host defense modulator 018 early 
FLTSVINRV F12L 404-412 (635) involved in plaque and EEV formation 042 early/late 
GLNDYLHSV O1L 247-255 (405) hypothetical protein 059 early 
      
HLA-B*0702:      
      
IPDEQKTIIGLg B15R 91-101 (143) hypothetical protein 183 early 
MPAYIRNTL J6R 303-311 (1286) DNA-dependent RNA polymerase subunit rpo147 090 early 
RPMSLRSTII O1L 335-344 (405) hypothetical protein 059 early 
a ORF, temporal expression and protein description according to VACV WR nomenclature (NCBI: NC_006998) and as 
described in (231). 
b Amino acid position in protein according to VACV strain Acambis 3000 Modified Virus Ankara (MVA) (NCBI: AY603355). In 
brackets, the number of amino acids of the protein is indicated. 
c Locus tag according to Vaccinia virus strain Acambis 3000 Modified Virus Ankara (MVA) (NCBI: AY603355).  
d  Sequence in VACV WR: ELIIHNPEL 
e  Previously B18R 
f ORF and protein description according to VACV COP nomenclature (NCBI: M35027), since protein is deleted in VACV WR. 
g  Sequence in VACV WR: IPDEQKT[IREISA]IIGL 
 
3.1.3.2  Comparison between the levels of viral protein expression and viral 
HLA ligand presentation 
An intriguing characteristic of the proteins processed to the identified HLA ligands 
was their exclusive temporal expression early or early/late during the viral life cycle in 
MVA infected B-LCL (Table 3.1) despite the unimpaired expression of late genes in 
these cells (data not shown). This was surprising, since it had been shown for cells 
other than DC that proteins with late temporal expression can already be detected 4 h 
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after infection, 6.5 h earlier than the time point at which the infected B-LCL were 
harvested for HLA ligand purification (231, 304). Therefore, we analyzed the levels of 
viral protein expression and viral HLA ligand presentation in infected B-LCL 
simultaneously. Comparative differential image analysis of 2D gels containing proteins 
from MVA- and mock-infected cells revealed several abundant proteins solely or 
predominantly expressed in the infected cells (Figure 3.3). Furthermore, we 
specifically checked for expression of the proteins which gave rise to HLA ligands by 
predicting their theoretical spot coordinates on the gels. Differentially detected 
protein spots were digested by trypsin and fragments were sequenced by LC-MS/MS. 
Peptide digestion products derived from proteins of both viral (Table 3.2) and human 
origin (data not shown) were detected. Six of 24 identified viral proteins were late 
viral gene products (Table 3.2) indicating that late proteins were available for 
proteasomal processing at the time cells were harvested for HLA ligand analysis. 
Under the conditions used for this experiment, several viral proteins would not be 
detected due to their extreme size or pI: B22R and G5.5R would be missed due to their 
low molecular weight of 7.3 kD each, while detection of E5R is unlikely due to its 
high pI of 10. Proteins detectable on the 2D gels had a MW of more than 14 kD and a 
pI between 4 and 9. Altogether, 69 MVA proteins do not match the above 
characteristics and thus most likely should not be detected by this method. 
Interestingly, there was little or no correlation between the relative abundance of 
intracellular viral proteins and directly processed viral peptides presented on HLA. 
Only two of the 24 most abundant MVA proteins were source proteins for identified 
HLA ligands, namely B8R (ligand KITSYKFESV18-27) and C7L (ligand KVDDTFYYV74-
82), although CTL determinants for other proteins had been described previously 
(Table 3.2). Interestingly, B8R and C7L provide immunodominant epitopes in mice 
and humans, respectively (96, 97, 99, 100, 107). On the other hand, eleven out of 13 
source proteins for which we found HLA ligands were not detected using this 
approach suggesting that most viral HLA ligands were derived from proteins of low 
abundance at 12.5 h post infection. 
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Figure 3.3 Analysis of differentially expressed intracellular proteins 12.5 h post 
infection. Representative 2D-PAGE images of experiments performed with protein extracts 
of mock-infected (A) and MVA-infected (B) B-LCL JY. (B) MVA proteins identified by LC-
MS/MS of tryptic digests are designated. Differentially expressed proteins identified as 
human are not indicated. (C) Alignment of gels A and B (gel A: red; gel B: blue; merged: 
black). The proteomic analysis was performed by Mirita Franz-Wachtel, Inga Buchen, 
Johannes Madlung, Claudia Fladerer and Tobias Lamkemeyer (Institute of Cell Biology, 
Proteome Center Tübingen, University of Tübingen). 
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Table 3.2    Intracellular MVA proteins identified in B-LCL by proteomic analysis 12.5 h post 
infectionc 
ORFa Temporal 
expressiona 
Mw 
theor./exp. 
pI 
theor./exp. 
Number 
of tryptic 
peptides 
detected 
Number of 
known  
HLA-A*0201 
or B*0702 
epitopes 
Number of 
other known 
HLA-A and -B 
epitopes 
A3L late 72.6/61.0 6.37/6.30 13 - 2 (101) 
A4L late 30.9/39.0 4.91/4.90 7 - - 
A6L late 43.1/40.0 5.71/5.60 19 2 (98, 99) - 
A37R early 29.8/27.0 5.61/5.50 10 - - 
A44L early 39.3/39.0 6.71/7.00 12 - - 
A46R early/late 27.6/32.0 4.85/4.90 4 1 (98) - 
B1R early 34.3/32.0 8.95/8.80 8 - - 
B8R early/late 31.1/35.0 6.81/5.70 8 1b 4 (99) 
B12R early 33.3/34.0 8.11/8.10 3 - - 
C7L early 18.0/18.0 5.95/5.90 3 1 (96-100),b 1 (99) 
E3L early/late 21.5/26.0 5.19/5.00 11 - 1 (101) 
E4L early/late 29.8/38.0 5.17/4.90 2 - - 
F2L early 16.4/17.0 8.53/5.60 6 - - 
F4L  early 36.9/38.0 4.92/4.90 11 1 (99) - 
F13L late 41.8/41.0 6.55/7.10 10 - - 
G8R early/inter-
mediate 
29.9/29.0 6.60/5.80 7 - 1 (99) 
H5R early/inter-
mediate 
22.3/34.0 6.86/5.60 3 - - 
H7R late 16.9/16.0 6.73/6.00 4 - - 
I3L early 30.0/34.0 5.68/5.50 11 - 2 (98, 99, 101) 
J2R early 18.6/19.0 5.55/5.80 4 1 (98) 1 (110) 
J4R early 20.7/25.0 8.56/7.10 3 - - 
K7R early 17.5/17.0 4.75/4.70 4 - - 
L4R late 28.4/28.0 6.64/5.70 7 - - 
N2L early 20.3/21.0 6.95/6.60 8 1 (99) - 
a ORF description and temporal expression according to VACV WR nomenclature (NCBI: NC_006998) and as described in 
(231). 
b Shown in this study, printed bold. 
c The proteomic anaylsis was performed by Mirita Franz-Wachtel, Inga Buchen, Johannes Madlung, Claudia Fladerer and 
Tobias Lamkemeyer (Institute of Cell Biology, Proteome Center Tübingen, University of Tübingen). 
 
3.1.3.3  Long-term recognition of HLA-A*0201 ligands by specific IFN-γ 
producing CD8+ T cells in MVA vaccinees 
We studied the immunogenicity of the identified HLA-A*0201 ligands by IFN-γ 
enzyme-linked immunospot (ELISPOT) assay of PBMC derived from two HLA-
A*0201 positive donors immunized twice with MVA. An initial screen of PBMC taken 
before vaccination and up to 30 days post boost (p.b.)2 indicated that immunization 
induced specific IFN-γ production in response to four out of five HLA ligands tested 
(Figure 3.4). Since specific responses against two peptides, A48R187-195 and C7L74-82, 
were seen in both donors and no responses were detected in PBMC isolated from 
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preimmune samples of either donor, we concluded that these responses were induced 
by immunization and were not generated by in vitro peptide/IL-2 stimulation prior to 
analysis. 
 
Figure 3.4 IFN-γ responses of MVA-immunized donors to MVA-
derived HLA-A*0201 ligand peptides varies with time post 
vaccination. Blood was taken from donors at the indicated time 
points. PBMC sensitization and IFN-γ ELISPOT assay were performed 
essentially as described in Materials and Methods except: PBMC were 
expanded by administration of peptide on d1 and a single dose of IL-2 
on day 3; the assay was performed without adding K562/A*0201 cells 
as APC; data was collected from single or duplicate measurements; 
spot forming cells (SFC) were calculated by subtracting the number 
of spots induced by an irrelevant HIV HLA-A*0201 epitope. 
 
We extended our study to the complete panel of HLA ligands and analyzed in vitro 
expanded PBMC taken 2.5 years p.b. by flow cytometry using combined 
MHC/peptide-tetramer and intracellular IFN-γ staining (Figure 3.5, Table 3.3). For all 
peptides except B8R18-27, tetramer positive CD8+ T cell populations were found in 
donor 1 (Figure 3.5, left panels), indicating that these HLA ligands are A*0201 
restricted CTL epitopes and are simultaneously recognized as part of the long-term 
memory response to MVA. CD8+ T cell populations identified by tetramers specific for 
eight out of eleven epitopes were functional and responded to in vitro stimulation 
with the specific MVA peptide by downregulating the TCR and producing IFN-γ 
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(Figure 3.5, right panels). Since the populations recognized by tetramers specific for 
the remaining three peptides, B19R207-215, A23R273-281 and D12L251-259, were small (less 
than 0.06%), our assay may not have been sensitive enough to detect production of 
IFN-γ by a fraction of these cells reliably. However, TCR downregulation as an 
indication of activation was clearly observed in response to two of these HLA ligands: 
B19R207-215 and A23R273-281. In donor 2, CD8+ T cell populations specific for eight out of 
twelve HLA ligands were detected by tetramer staining (Table 3.3). Six of these 
populations specifically responded to in vitro stimulation with TCR downregulation 
and IFN-γ production. Stimulation with E5R93-101 induced IFN-γ producing CD8+ T 
cells, which, however, were not stained by the matching tetramer, possibly due to a 
low affinity TCR (Table 3.3). 
 
 
Figure 3.5 CD8+ T cells specific for MVA-derived HLA ligands are HLA-A*0201 restricted and 
produce IFN-γ. Cells from donor 1 restimulated as described in Methods were treated for 7 h 
with either the MVA peptide indicated (right panels) or an irrelevant HIV HLA-A*0201 restricted 
epitope (left panels) prior to combined tetramer / intracellular IFN-γ staining. Gates were set 
on CD8+ lymphocytes and numbers indicate the percentage of cells in each quadrant. 
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Table 3.3   Comparison of CD8+ T cell responses specific for MVA-derived HLA ligands in MVA 
vaccinees 
   
 Donor 1 Donor 2 
     
 ELISPOT  
(1 stim.) 
Tetramer / intracellular IFN-γ 
(2 stim.) 
ELISPOT  
(1 stim.) 
Tetramer / intracellular IFN-γ 
(2 stim.) 
Peptidea,b IFN-γ c TCR d TCR↓d IFN-γ d IFN-γ c TCR d TCR↓d IFN-γ d 
         
B19R207-215 - + + - - - - - 
E5R93-101 - + + +/- + - - + 
G5.5R27-35 ++ + + + - + + + 
B22R178-186
e + + + +/- - + + +/- 
A23R273-281 + + + - - - - - 
B8R18-27 - - - - - - - - 
A48R187-195 +++ + + + + + +/- +/- 
D12L62-70 - + + + - + + - 
D12L251-259 - + - - - + +/- - 
C7L74-82 +++ + + + +++ + + + 
F12L404-412 ++ + + + + + + + 
O1L247-255 ++ + + + + + + + 
a ORF description according to VACV WR nomenclature (NCBI: NC_006998). 
b Amino acid position in protein according to VACV strain Acambis 3000 Modified Virus Ankara (MVA), (NCBI: AY603355). 
c Relative amounts of spot forming colonies determined by IFN-γ ELISPOT after 1 round of in vitro peptide/IL-2 
stimulation: + 18-60, ++ 61-200, +++ >200 per 5 x 105 PBMC  
d Relative percentage of CD8+ lymphocytes determined by combined tetramer / intracellular IFN-γ staining after 2 
rounds of in vitro peptide/IL-2 stimulation: TCR: + tetramer-positive cells, - tetramer-negative; TCR↓: + TCR 
downregulation detectable by tetramer staining for majority of tetramer-positive T cells, +/- TCR downregulation 
detectable for minority of tetramer-positive cells, - tetramer-negative; IFN-γ: + IFN-γ producing cells, +/- few IFN-γ 
producing cells, - no IFN-γ producing cells. 
e ORF description according to VACV COP nomenclature (NCBI: M35027), since protein is deleted  in VACV WR. 
 
Analysis of the same samples by IFN-γ ELISPOT assay after a single round of in vitro 
expansion gave similar results: eight epitopes were recognized in at least one donor 
and four were recognized in both (Figure 3.6). In addition, IFN-γ production in 
response to A23R273-281 by PBMC from donor 1 was observed, confirming this HLA 
ligand as a T cell epitope. 
In summary, all twelve MVA-derived HLA-A*0201 ligands which we identified were 
immunogenic, eleven of these provided long-term T cell memory. We demonstrate 
that the cellular immune response to MVA infection is based on simultaneous 
recognition of many different CTL epitopes with donor-specific variations in the 
epitope-specific CD8+ T cell frequencies and in the epitope-hierarchy. This finding is 
consistent with earlier analyses of human T cell responses to MVA (100) and other 
viruses such as CMV (318), EBV (319) and Influenza virus (160). Four HLA ligands 
proved to be common epitopes in the long-term response to MVA vaccination: C7L74-
82, the immunodominant epitope, as well as A48R187-195, F12L404-412 and O1L247-255. 
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Figure 3.6 MVA-immunized donors show IFN-γ production in 
response to a broad repertoire of MVA-derived HLA-A*0201 
ligands. PBMC expansion and IFN-γ ELISPOT assay were carried out as 
described in Materials and Methods. SFC were determined in 
triplicate; error bars indicate the SEM. Values three times higher 
than the HIV-peptide induced background were considered as 
positive. 
 
3.1.3.4  Long-term recognition of MVA-derived HLA-A*0201 ligands by CD8+ 
T cells from Dryvax® vaccinees 
Since we observed T cells specific for the MS-identified HLA ligands more than 2 
years after immunization in MVA vaccinees, we investigated long-term memory T cell 
responses specific for these peptides in PBMC from donors vaccinated with the VACV 
Dryvax® vaccine more than 25 years ago. Since the sequences of the MVA-derived 
HLA-A*0201 ligands are identical to those in VACV Dryvax® (Table 3.4), we 
anticipated that these ligands could also be immunogenic in the course of classical 
smallpox vaccination. Analysis of tetramer-specific CD8+ T cells derived from in vitro 
expanded PBMC of three HLA-A*0201 positive Dryvax® vaccinees at 25 to 45 years 
p.b. revealed specificity for seven of the identified HLA-A*0201 ligands (Table 3.5). All 
three donors contained CD8+ T cells specific for two of the common epitopes 
identified in the previous experiments with MVA vaccinees, C7L74-82 and F12L404-412, 
while two donors contained T cells specific for G5.5R27-35 and O1L247-255. These results 
suggest that one round of prime-boost vaccination with MVA or Dryvax® was 
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sufficient to induce a long-lived cellular immune response to several identical 
epitopes. 
To determine if the MVA epitopes described in this study can potentially cross-protect 
against infection by other VACV strains or orthopoxviruses, we compared the 
sequences of the MVA-derived HLA ligands to those derived from VACV Dryvax®, 
VACV WR and VARV, as well as monkey pathogenic MPXV, which has been 
described recently to cause human disease (320). Seven sequences were conserved 
between all strains (Table 3.4), including three of the common epitopes shown to be 
cross-reactive between MVA and VACV Dryvax® (Table 3.5). While the 
immunodominant epitope C7L74-82 is identical in the VACV strains, it differs by two 
amino acids in MPXV, making it unlikely that this epitope can provide protection 
against MPXV. 
 
Table 3.4  Comparison of peptide sequences of MVA-derived HLA ligands among orthopox-
viruses 
      
Peptide MVAa VACV Dryvaxb VACV WRc VARVd MPXVe 
      
HLA-A*0201:      
      
B19R207-215 KLIIHNPEL * ELIIHNPEL ELIIHNPAL ELIIHNPEL 
E5R93-101 KLFSDISAI * * * KLFSDISVI 
G5.5R27-35 SLKDVLVSV * * * * 
B22R178-186 TLLDHIRTA * deleted * TLLDHILTA 
A23R273-281 ALDEKLFLI * * * * 
B8R18-27 KITSYKFESV * * TITSYKFESV * 
A48R187-195 IVIEAIHTV * * * * 
D12L62-70 KLFTHDIML * * * * 
D12L251-259 RVYEALYYV * * * * 
C7L74-82 KVDDTFYYV * * * KVDYTLYYV 
F12L404-412 FLTSVINRV * * * * 
O1L247-255 GLNDYLHSV * * * * 
      
HLA-B*0702:      
      
B15R91-101 IPDEQKTIIGL IPDEQKT-IIGL IPDEQKT-IIGL IPDEQKT-IIGL IPDEQKT-IIGL 
J6R303-311 MPAYIRNTL * * * MPTYIRNTL 
O1L335-344 RPMSLRSTII * * * * 
a VACV strain Acambis 3000 MVA (NCBI: AY603355) 
b VACV strain Acambis 2000 (NCBI: AY313847), substrain isolated from the Dryvax® vaccine.  
c VACV strain Western Reserve (NCBI: NC_006998) 
d VARV strain Bangladesh 1975 (NCBI: L22579)  
e MPXV strain Zaire (NCBI: NC_003310) 
* = identical sequence to MVA 
- = IREISA; amino acid sequence deleted in MVA 
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Table 3.5 Comparison of CD8+ T cell responses to 
shared vaccinia epitopes in VACV Dryvax® 
vaccineesa 
    
Peptideb,c Donor 3 
(25 y) 
Donor 4 
(29 y) 
Donor 5 
(> 40 y) 
    
B19R207-215 0.08 0.02 0.02 
E5R93-101 0.03 0.04 0.02 
G5.5R27-35 0.10 0.06 <0.01 
B22R178-186
d 0.32 0.03 0.01 
A23R273-281 0.01 0.02 <0.01 
B8R18-27 0.04 0.01 0.03 
A48R187-195 0.04 0.02 1.19 
D12L62-70 0.01 0.02 0.01 
D12L251-259 0.03 0.02 0.01 
C7L74-82 0.14 0.28 1.33 
F12L404-412 0.08 0.08 0.19 
O1L247-255 0.16 0.09 0.01 
a Tetramer staining was carried out after one round of in vitro 
peptide/IL-2 stimulation. Tetramer+ CD8+ CD4- lymphocytes 
>0.05% are considered significant and indicated in bold.  
b ORF description according to VACV WR nomenclature (NCBI: 
NC_006998). 
c Amino acid position in protein according to VACV strain 
Acambis 3000 Modified Virus Ankara (MVA), (NCBI: AY603355). 
d ORF description according to VACV COP nomenclature (NCBI: 
M35027), since protein is deleted  in VACV WR. 
 
3.1.3.5  Vaccination with actual HLA ligands provides protection against a 
lethal VACV challenge in HLA-A*0201-transgenic mice 
All of the HLA ligands identified in this study were peptides derived from early viral 
proteins. Recently, we found that T cells recognizing such peptides were capable of 
dominating the response to a secondary VACV infection. Therefore we tested whether 
vaccination with the identified peptides would be able to clear an orthopoxviral 
infection. Importantly, HLA-A*0201 transgenic HHD mice were fully protected 
against a lethal respiratory challenge with the virulent VACV strain WR after a single 
immunization with a pool of three peptides derived from early gene products 
identified in this study (B8R18-27, G5.5R27-35 and C7L74-82) (Figure 3.7b). In contrast, 
peptides from late viral proteins (A6L6-14, H3L184-192 and I1L211-219) which dominate the 
primary response in this mouse model after MVA immunization ((112), Figure 3.7a) or 
induced much higher CD8+ T cell frequencies when applied in this study as pooled 
peptide vaccine (Figure 3.7a), were less protective. These animals showed a dramatical 
loss of weight (similar to the control group) and suffered prolonged disease progression 
(> 25 days), while all mice in the early peptide group were fully recovered by day 14. 
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Of note, the addition of CpG ODN as an adjuvant in all peptide vaccine preparations 
showed some unspecific protective capacity as demonstrated by survival of control 
peptide vaccinated mice which was most likely mediated by the innate immune 
response. 
 
 
Figure 3.7 Vaccination with HLA ligands provides protection against a lethal VACV challenge 
in HLA-A*0201-transgenic mice. Mice were immunized s.c. with pools of peptides derived from 
either early (Early Pep pool: B8R18-27, G5.5R27-35, C7L74-82) or late viral gene products (Late Pep 
pool: A6L6-14, H3L184-192, I1L211-219) or control peptides (Control Pep pool: Tyr369-377, FluM58-66, 
pp65495-503) or i.m. with MVA wt (108 IU) or PBS. On day 7 mice were bled and PBMC were tested 
for reactivity against the immunized peptides using intracellular IFN-γ staining. Reactivity 
against control peptides was below 0.1%. MVA-immunized mice were tested for reactivity 
against the early or late peptide pool (A). On day 8 mice were challenged with VACV WR (106 
PFU) intranasally. (B) Relative weight loss over time. In the mock-immunized group, all mice 
were dead by day 7, one mouse in the control and one mouse in the late group also died on day 
7 (n=5). This experiment was performed by Wolfgang Kastenmüller, Georg Gasteiger, and Ingo 
Drexler (Institute of Virology, Technical University Munich and Helmholtz Center Munich). 
 
3.1.4 Discussion 
Identification of viral HLA ligands by LC-MS/MS analysis has resulted in a better 
understanding of the cellular anti-viral immune response. The major challenge has 
been to find a limited number of signals derived from the virus in the multitude of 
self-peptides. Planz et al. used a tedious “predict-calibrate-detect” strategy to identify 
an HLA ligand from borna disease virus (131), while de Jong and van Els have 
developed elegant approaches based on in silico subtraction and metabolic labeling to 
study measles and respiratory syncytial viruses (132, 133). Unfortunately, these 
strategies have not become routine and the number of viral HLA ligands known is still 
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very limited. So far, only one MVA-derived HLA ligand has been found by LC-MS/MS 
analysis of peptides isolated from infected cells (134).  
The strategy described in this study, differential analysis of HLA ligands by chemical 
stable isotope labeling after purification of peptides, combines several advantages. 
First, comparative measurements of HLA ligands from infected and mock-infected 
cells eliminate the need for ligand prediction. Second, identification of single peptide 
peaks in a survey LC-MS scan is time-effective using manual evaluation, and 
algorithms providing automatic evaluation are expected to become available shortly. 
Third, the presence of a constant normalizing signal based on the self-peptides limits 
the requirement for reproducibility in chromatographic retention, peptide ionization 
and selection for fragmentation. Finally, this approach can be applied to tissue taken 
from any organism, and may allow comparative analysis of different sites of infection.  
Using differential stable isotope labeling of HLA ligands purified from infected and 
mock-infected cells, we discovered fifteen MVA-derived ligands, twelve restricted to 
HLA-A*0201 and three to HLA-B*0702 (Table 3.1). Eight ligands represent novel 
sequences. One peptide, A48R187-195, had been described by Johnson et al. (134), and six 
ligands matched known CTL epitopes (references see Table 3.6). Nine proteins from 
which HLA ligands were derived are among the 29 previously described immunogenic 
early proteins (93), and four proteins, B19R, E5R, G5.5R and B15R, were newly 
identified in this study to contain relevant human CTL epitopes (Table 3.6). The 
proteins bearing HLA ligands functionally belong to two groups: proteins with 
immunomodulatory or host range and virulence function (B8R, B15R, B19R, C7L and 
F12L (231, 321, 322)) and proteins functionally connected to DNA replication or 
transcription (E5R, A48R, G5.5R, A23R, D12L and J6R (231)). The function of O1L is 
unknown. The novel immunogenic proteins B15R and B19R are known cytokine 
receptors of VACV and play a pivotal role in the VACV mediated interference with 
the immune response (321, 323). Less is known about the function of the two other 
proteins newly identified as T cell epitope sources: E5R is located in cytoplasmic sites 
of viral DNA replication, where it associates with the proteins H5R and E3L, which 
were both detected as abundant proteins in this study (324); G5.5R has been described 
as a subunit of the DNA-dependent RNA polymerase (325). Two proteins, O1L and 
D12L, bear two HLA ligands each, suggesting high immunogenicity. 
Notably, we exclusively detected HLA ligands from viral gene products expressed 
early or early/late during the viral life cycle (231) (Table 3.1). This is consistent with 
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our previous observation that presentation of peptides derived from late viral antigens 
to specific T cells by infected mouse target cells was very inefficient, but could be 
restored by the expression of the same viral antigens under the control of early 
promoters (112). This finding indicates a bias for early viral antigens to be processed 
and presented on MHC class I molecules of infected APC. However, since T cell 
responses against late viral proteins are found in humans and mice, the data support 
the concept that T cells are efficiently crossprimed upon MVA vaccination (316), 
particularily, when considering that late protein synthesis is blocked in MVA infected 
DC (304). 
Several mechanisms can be invoked to explain the inability to detect HLA ligands 
from late proteins on infected cells. Early and late viral gene products are transcribed 
and translated in distinct cellular compartments (219, 220) possibly resulting in 
variable availability for antigen processing. Alternatively, the initiation of cell death 
during the course of infection may reduce the loading capacity of the cellular antigen-
presenting machinery thus reducing the abundance of HLA ligands from late viral 
proteins (188).  
Several studies have described a number of early as well as late epitopes of MVA and 
replication-competent VACV strains based largely on T cell analysis of immunized 
donors (95-100, 103). Our data concurs with the finding that VACV-specific CTL 
epitopes are predominantly derived from early proteins (99). We also confirm C7L74-82 
as the immunodominant epitope, and F12L404-412 and O1L247-255 as subdominant 
epitopes. However, using the MS-based technique we were able to detect only four of 
the 24 published HLA-A*0201 restricted MVA epitopes as HLA ligands, but then only 
two out of the remaining 20 were derived from source proteins, from which we found 
HLA ligands (Table 3.6). One reason might be that different virus strains have been 
used for these studies. Particularly, replication-competent VACV strains might differ 
in pattern of antigen presentation or immunogenicity compared to MVA.  In addition, 
several other factors may affect this limited overlap between the actual repertoire of 
MVA HLA ligands described here and previously identified HLA-A*0201 restricted 
CTL determinants described for MVA or replication-competent VACV. First, 
technical restrictions within the LC-MS/MS analysis are likely to prevent the 
detection of all MVA-derived HLA ligands. Even if a peptide is presented by a 
sufficient number of HLA molecules to produce a signal with sufficient intensity, a 
peptide peak may be missed due to co-elution of peptides of similar molecular weight 
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or suppression of peptide ionization by co-eluting peptides (326). Furthermore, some 
peptide sequences are difficult to detect due to their chemical characteristics, as may 
be the case for the epitope B22R79-87 (96, 100) containing a cysteine residue which can 
react by oxidation. Another possible reason for the limited overlap might be inherent 
to the in vitro infection model that we chose to generate the material for our HLA 
ligand analysis. We used one defined cell type and analyzed one time point post 
infection. In addition, cross-presentation of epitopes might add to the repertoire of 
CTL determinants in vivo. A third explanation may be the individual heterogeneity of 
subdominant epitopes, e.g. many VACV Dryvax® epitopes were characterized solely 
by IFN-γ production in a single donor (99). In contrast, ten out of twelve HLA-A*0201 
ligands identified in this study were recognized by more than one of the five donors 
tested suggesting that they are immunologically highly relevant. Finally, the limited 
overlap might also be a result of differing T cell assay protocols. In contrast to some 
other groups, we restimulated the PBMC of vaccinees twice in order to clearly detect 
the T cells with specificity for the HLA ligands presented by MVA-infected cells. 
In summary, the MS-based technique used here seems to be a reliable method to 
identify clinically relevant viral CTL epitopes and could be applied to other large-
genome pathogens or recombinant antigens expressed by MVA. We identified twelve 
HLA-A*0201 and three HLA-B*0702 ligands derived from MVA. Nine of these 15 
peptides were novel. All HLA-A*0201 ligands were shown to be actual CTL epitopes in 
MVA-immune donors. These peptides, preferably common and more dominant 
epitopes such as C7L74-82, F12L404-412, G5.5R27-35, O1L247-255 and A48R187-195, are essential 
to monitor CD8+ T cell responses to MVA-based vaccines in clinical trials and may be 
used as correlates of protection. In addition, they seem suitable to be included e.g. as 
an epitope-based component in a smallpox vaccine which might be considered as a 
low-cost, safe and stable alternative to traditional vaccines against bioterrorist 
smallpox threats.  
Poxviral HLA ligands provide long-term immunity 
 68
Table 3.6 Newly identified and published epitopes of the viral HLA ligand source proteins  
       
ORF (temporal 
expression)a 
Epitope 
locationb 
Sequence MHC 
restriction 
Ligand on 
B-LCL JY 
CD8+ T-cells 
in MVA-
vaccinees 
References 
       
B19R (early) 207-215 KLIIHNPELd HLA-A*0201 yes yes - 
E5R (early) 93-101 KLFSDISAI HLA-A*0201 yes yes - 
G5.5R (early) 27-35 SLKDVLVSV HLA-A*0201 yes yes - 
B15R (early) 91-101 IPDEQKTIIGLe HLA-B*0702 yes n/a - 
B22R (early)c 178-186 TLLDHIRTA HLA-A*0201 yes yes - 
             79-87 CLTEYILWV HLA-A*0201 no yes (96, 100) 
 72-80 TVADVRHCL HLA-B*07 n/a n/a (110) 
A23R (early/late) 273-281 ALDEKLFLI HLA-A*0201 yes yes - 
 287-295 HDVYGVSNF HLA-B*4403 n/a n/a (101) 
 297-305 IGMFNLTFI H2-Db n/a n/a (107) 
B8R (early/late) 18-27 KITSYKFESV HLA-A*0201 yes yes - 
 110-118 TEYDDHINLf HLA-B*4001 n/a n/a (99) 
 124-132 DMCDIYLLY HLA-A*2601, 
HLA-A*2902, 
HLA-A*0101 
n/a n/a (99) 
 138-147 FGDSKEPVPY HLA-A*2601, 
HLA-A*2902, 
HLA-A*0101 
n/a n/a (99) 
 262-271 FLSMLNLTKYg HLA-A*2902, 
HLA-A*0101 
n/a n/a (99) 
 20-27 TSYKFESV H2-Kb n/a n/a (97, 107) 
A48R (early/late) 187-195 IVIEAIHTV HLA-A*0201 yes yes (134) 
 58-66 TYNDHIVNL HLA-A*2301 n/a n/a (101) 
D12L (early/late) 62-70 KLFTHDIML HLA-A*0201 yes yes - 
 251-259 RVYEALYYV HLA-A*0201 yes yes (98) 
 14-22 VLLPFYETL H2-Kb n/a n/a (107) 
C7L (early) 74-82 KVDDTFYYV HLA-A*0201 yes yes (96, 97, 99, 100) 
 31-40 KLKIISNDYK HLA-A*0301 n/a n/a (99) 
F12L (early/late) 404-412 FLTSVINRV HLA-A*0201 yes yes (99) 
 286-295 NLFDIPLLTV HLA-A*0201 no n/a (99) 
J6R (early) 303-311 MPAYIRNTL HLA-B*0702 yes n/a (99, 103) 
 332-340 NQVKFYFNK HLA-A*0301 n/a n/a (99) 
 542-551 AGLLSDHKSN H2-Kb n/a n/a (105) 
O1L (early) 247-255 GLNDYLHSV HLA-A*0201 yes yes (99) 
 335-344 RPMSLRSTII HLA-B*0702 yes n/a (99) 
a ORF description and temporal expression according to VACV WR nomenclature (NCBI: NC_006998) and as described in 
(231). 
b Amino acid position in protein according to VACV strain Acambis 3000 Modified Virus Ankara (MVA), complete genome 
(NCBI: AY603355) or as described by the reference, if sequence differs in MVA. 
c ORF and protein description according to VACV COP nomenclature (NCBI: M35027), since protein not present in VACV 
WR. 
d Sequence in VACV WR: ELIIHNPEL 
e Sequence in VACV WR: IPDEQKTI--- 
f VACV Dryvax® CTL epitope; homologous sequence in MVA: TEYDDH--- 
g No homologous sequence in MVA. 
n/a, not applicable 
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3.2 MVA infection upregulates presentation of cytoskeleton-
derived self-peptides on HLA-A*0201 
3.2.1 Introduction 
Myocarditis is an inflammatory heart disease often associated with a previous viral 
infection (327-331). VACV-based smallpox vaccination has been reported to induce 
autoimmune eosinophilic-lymphocytic myocarditis as a serious side effect (134, 236, 
240, 241). It has been diagnosed by biopsy in human individuals shortly after 
vaccination providing histological evidence for eosinophil-mediated cardiac myocyte 
necrosis (242). The lymphocytic component consisted mainly of CD3+ T cells, of 
which about 25% were CD8+. PCR showed that myocytes were virus-free.  
It has been suggested that myocarditis may develop due to autoimmune responses 
directed against cardiac tissue (332-336). The inflammatory immune response caused 
upon infection may break tolerance by mechanisms of molecular mimicry, bystander 
activation, and loss of immune regulation (337-342). The innate immune response to 
infection and release of cardiac myosin or other cardiac antigens may contribute to the 
overall enhanced inflammatory state in the myocardium (331). Once initiated, the 
immune responses leading to myocarditis can be perpetuated by exposed and 
presented cardiac antigens in the presence of inflammatory cytokines (330, 343, 344). 
A marked increase in expression of MHC class I and II molecules by the myocardium 
of patients with active myocarditis has been shown (327).  
Recently, CD8+-based autoimmunity has been demonstrated to be induced by DCs 
during HIV infection by cross-presentation of caspase-cleaved apoptotic self antigens 
mainly derived from the cytoskeleton (345). The chronic T cell activation in HIV-
patients has been shown to be largely attributable to T cells specific for multiple 
subdominant self peptides rather than HIV-specific T cells.  
We hypothesized that presentation of human self-HLA ligands on virus-infected cells, 
which are lacking on non-infected cells, might induce self-reactive T cells during 
infection. The technique used to identify MVA-derived HLA class I ligands, 
differential analysis of peptides presented by MVA infected and mock-infected cells, is 
ideal to identify not only viral HLA ligands but also self-ligands which are specifically 
presented by infected cells or whose presentation is upregulated upon viral infection. 
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No myocarditis cases have been reported with MVA so far, suggesting that the 
attenuated virus is not capable of inducing autoimmune-reactive cells. Yet, cells 
infected by replication-competent VACV might upregulate the same human self-
ligands as the attenuated VACV strain MVA. Therefore, we analyzed the relative 
abundance of human self-HLA class I ligands on MVA-infected versus mock-infected 
cells.  
3.2.2 Results 
3.2.2.1  Identification of differentially overpresentated human HLA-A*0201 
ligands upon MVA infection 
In order to identify human self-ligands specifically or overpresented by HLA-A*0201 
on the human B-LCL JY upon infection with MVA, we differentially analyzed the 
ligands isolated from MVA- and mock-infected cells after 12.5 h of infection. For this 
purpose, HLA-presented peptides were chemically modified by covalently-linked 
stable isotope tags: peptides isolated from MVA-infected cells with heavy (deuterated, 
D4) nicotinic acid (NIC) and peptides isolated from mock-infected cells with light 
(hydrogenated, H4) NIC. The two pools of tagged peptides were mixed, and the 
peptides were separated by nanoHPLC and analyzed online by MS. HLA ligands 
present on both MVA- and mock-infected cells representing human self-peptides were 
detected as doublets with a mass difference of 4 Da due to the four deuterium atoms of 
D4NIC (Figure 3.1, lower central panel) replacing four hydrogen atoms present in 
H4NIC. Single peaks may either represent peptides derived from viral proteins or from 
human self-proteins which are specifically synthesized and/or degraded upon 
infection. Peptides were sequenced by fragmentation using LC-MS/MS analysis.  
Although no human self-HLA ligands exclusively presented on the infected cells were 
identified, two out of 409 self-ligands evaluated were found highly overpresented 
upon MVA-infection (Figure 3.8). The HLA-A*0201-restricted peptides were derived 
from two proteins associated with the cytoskeleton, myosin 1G (ALVDHVAEL, 
upregulated by factor 5.3, and C14orf49/nesprin-3 (ALAQRLLEV, upregulation by 
factor 6.6). The abundance of 95% of all ligands differed maximally by the factor of 1.7 
(log2 [Intensity HLA ligands(D4NIC/H4NIC)] = -0.8 to 0.8; Figure 3.8). Taking into 
account that only about 50% of analyzed cells were infected, upregulation of the 
ligands was likely even more pronounced than by the evaluated factors. 
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Figure 3.8 Two out of 409 human HLA ligands evaluated were overpresented 
on B-LCL JY upon MVA-infection. Normalized intensity ratios of peptide doublet 
peaks in the LC-MS analysis performed with an 1:1 mix of the peptide pools 
isolated from MVA-infected (D4NIC-modified) and mock-infected (H4NIC-modified) 
cells were evaluated. Almost all peptides were presented in equal abundancies 
on infected and mock-infected cells. Peptides upregulated upon MVA-infection 
were identified by LC-MS/MS analysis as derived from myosin 1G (factor 5.3) and 
nesprin-3 (factor 6.6). 
3.2.3 Discussion and Outlook 
By analyzing the relative abundance of directly presented HLA class I ligands of 
MVA-infected versus mock-infected cells, two human self-HLA ligands were found 
highly upregulated in MVA-infected B-LCL, suggesting either specifically induced 
synthesis and/or degradation upon infection. Strikingly, both peptides were derived 
from proteins associated with the cytoskeleton. Nesprin-3 is an outer nuclear 
membrane protein binding to the cytoskeletal linker protein plectin which can 
directly cross-link the actin and the intermediate filament cytoskeletal system (346). 
Myosin 1G is a member of the class I myosin proteins, which are nonfilament-forming 
myosins thought to play a role in intracellular transport and locomotion (347). It is 
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expressed in cardiac tissue (see www.genecards.org: GeneCard for protein-coding 
MYO1G, Microarray Integrated Expression by GeneNote and GNF GeneAtlas Data). 
Cytoskeletal alterations have been shown upon VACV-infection: formation of virally-
induced microvilli, disruption of actin stress fibres and formation of actin tails in the 
cytoplasm of the host (348, 349). Morevoer, cytoskeletal derived proteins have been 
shown to play a major role in virally induced autoimmune reactions including 
myocarditis (345, 350). It is therefore imaginable that the increased presentation of the 
self-HLA ligands derived from nesprin-3 and myosin 1G in association with infection 
might be capable of inducing an autoimmune response in case the infection is virulent. 
As MVA, replication-competent VACV might upregulate the two human self-HLA 
ligands in host cells, perhaps even in a more pronounced manner due to complete 
synthesis and egress of virions. It remains to be shown, whether VACV Dryvax®-
vaccinees, who had suffered from autoimmune reactions following vaccination, carry 
memory CD8+ T cells recognizing these two ligands.  
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4 Results and Discussion Part II  
4.1 Identification of natural MHC class II presented 
phosphopeptides and tumor-derived MHC class I 
phospholigands  
This chapter has been submitted by the authors below for publication. 
 
Verena S. Meyer,* Jörg Hennenlotter,† Hans-Georg Rammensee,* Stefan Stevanović,*1  
*Department of Immunology, Institute of Cell Biology, University of Tübingen, D-
72076 Tübingen, Germany; †Department of Urology, University of Tübingen; 
1corresponding author 
 
The author of this thesis designed, performed and evaluated the experiments leading 
to the results described in this chapter. Tissue was excised by Jörg Hennenlotter†. 
Peptide isolation from tissue and synthesis of peptides were done by Anneke 
Neumann* and Patricia Hrstić*, respectively.  
 
Abbreviations used in this paper: B-LCL, B lymphoblastoid cell line; HLA, human 
leukocyte antigens; LC-MS, nanoHPLC-coupled MS analysis; LC-MS/MS, nanoHPLC-
coupled tandem MS analysis; MHC, major histocompatibility complex; m/z, mass to 
charge ratio of peptide ion; pS, phosphoserine; pT, phosphothreonine; RCC, renal cel 
carcinoma 
4.1.1 Abstract 
MHC molecules present protein-derived peptides to T lymphocytes. By developing 
TiO2-based microcentrifugation columns, we identified the first phosphorylated MHC 
class I ligands from tumor tissue (renal cell carcinoma) and, by comparison to healthy 
renal tissue, found one Brf1-derived ligand as potentially tumor-associated. We 
further discovered the first natural phosphorylated MHC class II ligands. They 
revealed several novel phosphorylation sites of significant transmembrane receptors, 
such as Frizzled 6, CXCR4 and CD20.  
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4.1.2 Introduction 
Major histocompatibility complex (MHC) molecules, also referred to as human 
leukocyte antigens (HLA), present peptides to be recognized by the T cell receptor of 
T lymphocytes. There are two classes of MHC molecules differing in the origin and 
length of the peptides presented and the T cells recognizing the peptide/MHC-
complexes (351). Peptides which are produced endogenously and are degraded to a 
length of 8 to 12 amino acids by the proteasome and other proteases in the cytoplasm 
and endoplasmic reticulum are presented by MHC class I molecules (352-354). In 
contrast, MHC class II molecules bind peptides which are mostly derived from 
exogenous or transmembrane proteins but also from cytosolic proteins and are 
degraded to a more variable length of 9 to 25 amino acids by various proteases 
originating from the lysosomal compartment (355-361). Peptide/MHC class I-
complexes are recognized by CD8+ T cells, also called cytotoxic T cells (76-78), those of 
MHC class II are recognized by CD4+ T cells including TH1 cells, which exert helper 
activity for the induction and maintenance of CD8+ T cells via activation of antigen 
presenting cells and secretion of cytokines (57, 58). Recognition of a peptide derived 
from a disease-associated protein, e.g., a viral or a tumor-specific protein, in presence 
of a costimulatory signal triggers a T cell-mediated immune response (for review see 
(54)). Anti-tumor immunity optimally requires the participation of both tumor cell-
directed cytotoxic CD8+ T cells and CD4+ T helper cells (362-367).  
Tumor cells differ from non-malignant cells in the activity of protein kinase pathways 
regulating cell growth, differentiation, and apoptosis (136, 178, 179).  Endogenous 
MHC class I peptides containing a posttranslational phosphorylation are discrimated 
from non-modified peptides by CD8+ T cells in vivo (176, 195, 196). Hence, peptides 
containing a tumor-associated phosphorylation represent potential tumor antigens 
(176). By comparing the repertoires of MHC class I bound phosphopeptides of cancer 
cell lines with the one of a B lymphoblastic cell line (B-LCL), phosphopeptides 
restricted to the tumor cell lines and common to all tumor cell lines studied could be 
identified (176). 
Phosphopeptide enrichment is essential for specifically identifying MHC-presented 
phosphopeptides in the multitude of non-phosphorylated peptides. Several methods 
have been developed to enrich phosphorylated peptides (200). Yet, most approaches 
have been used in the field of proteomics investigating peptides generated typically by 
MHC class II phospholigands and tumor-derived MHC class I phospholigands  
 76
tryptic digestion. These peptides share a certain physicochemical behaviour, since 
digestion products contain lysine at the C-terminus and are typically longer than 
MHC class I peptides. Zarling et al. (176, 196) have been successful in enriching MHC 
class I phosphopeptides from cell lines by using Fe3+-immobilized metal-affinity 
chromatography linked to C18-HPLC-coupled mass spectrometry (LC-MS). However, 
MHC class II presented phosphopeptides have not been found using this technique 
although several cell lines have been searched for (196). Yet, it has been demonstrated 
that CD4+ T cells can distinguish a phosphorylated MHC class II epitope from the non-
phosphorylated peptide (368).  
For application in immunotherapy, it is necessary to investigate whether a peptide 
containing a potentially tumor-associated phosphorylation is presented in vivo by a 
patient’s tumor. Thus, it is crucial to not only investigate cell lines (176) but actual 
tumor tissue. In this study, we show that MHC class I presented phosphopeptides can 
be isolated from renal cell carcinoma (RCC) tissue and can be identified by HPLC-
coupled mass spectrometry after offline-enrichment by a newly developed TiO2-based 
centrifugation technique. In order to identify potentially tumor-restricted 
phosphopeptides we compared the repertoire of phosphopeptides presented by a 
patient’s tumor tissue to the one presented by the same patient’s healthy renal tissue.  
Moreover, by applying the TiO2-microcentrifugation technique, we enriched and 
identified the first phosphopeptides naturally presented by MHC class II molecules of 
an EBV-transformed B-LCL and a tumor cell line. This finding clearly contradicts the 
former observation that phosphorylated peptides may only be presented by MHC class 
I molecules  (196). We demonstrate that phosphorylated MHC class II ligands contain 
phosphosites of plasmamembrane receptors involved in cancerogenesis and thus 
represent a potential new source for tumor-specific CD4+ T cell antigens.  
4.1.3 Results 
4.1.3.1  Offline-enrichment of MHC presented phosphopeptides by TiO2-
microcentrifugation columns 
To perform this study, we advanced an offline-technique using TiO2-microcolumns, 
which was established by Larsen et al. (207), by the development of centrifugation 
tubes (Figure 4.1). In contrast to air pressure created manually with a syringe as 
described by Larsen et al. (207), centrifugation allows for a stable flow of solvents 
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through the microcolumns. Enrichment of synthetic peptides (Table 4.1) showed 
quantative separation of phosphopeptides from non-phosphorylated peptides (Figure 
4.2). Yet, two phosphorylated peptides were not retained by the column: 
SYVKpTKMGL and KRFpSFKKSF. Both peptides contained basic amino acids next to 
or indirectly surrounding the phosphorylated residue (basic amino acids printed bold 
in Table 4.1). In contrast, a peptide equivalent to SYVKpTKMGL but containing acidic 
residues instead of the basic ones next to phosphothreonine (peptide SYVDpTEMGL, 
(Table 4.1) was retained by TiO2. This suggests that enrichment of peptides with two 
or more basic residues next to or surrounding the phosphogroup might be missed by 
this method. Importantly, peptides in the flowthrough which have not bound to TiO2 
may be analyzed as well (Figure 4.2). Thus, the method allows analysis of both 
phosphorylated and non-phosphorylated MHC ligands of a sample using the eluate 
and the flowthrough, respectively. We established a centrifugation protocol both for 
MHC class I and class II peptides, the latter requiring longer centrifugation times and 
higher g values due to their length (see Material and Methods). 
 
Figure 4.1 Preparation of TiO2-microcentrifugation 
columns (from right to left). GELoader tips are 
loaded with TiO2 as described by Larsen et al. (207). 
 
Table 4.1 Synthetic peptides used for 
phosphopeptide enrichment (Figure 4.2) 
Peptide [M+H]2+ eluate flowthrough
ALASHLIEA 462.8 - +
ALNELLQHV 518.8 - + 
RVAPEEHPVL 573.8 - + 
VLRENTSPK 522.3 - + 
VLRENTpSPK 562.3 + - 
RLDpSYVRSL 594.8 + - 
MPHEKHYpTL 618.3 + - 
SYVDpTEMGL 547.7 + - 
SYVKpTKMGL 553.8 - + 
KRFpSFKKSF 627.9 - + 
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Figure 4.2 MS analysis of the ten synthetic peptides listed in Table 4.1. 
Before enrichment, flowthrough (combined flowthrough of the sample and 
washing solutions), eluate. P = Phosphopeptide. Synthesis of peptides was done 
by Patricia Hrstić (Department of Immunology, Institute of Immunology, 
University of Tübingen). 
 
4.1.3.2  Identification of phosphorylated MHC class I ligands from tumor 
tissue and corresponding healthy tissue 
To identify potentially tumor-restricted phosphorylated HLA ligands, MHC class I-
peptide complexes were extracted by immunoaffinity chromatography from a patient’s 
RCC tissue (classified T1bNxM1) and from surrounding healthy tissue expressing HLA-
A*02, -A*24, -B*07, -B*35. Peptide ligands were separated from MHC molecules by 
acidic elution and size exclusion filtration. Peptides derived from tumor and healthy 
tissue were differentially labled by stable isotopes (deuterated and hydrogenated 
nicotinic acid) giving respective peptides a mass difference of 4 Da. Phosphopeptides 
from both modified pools were enriched using the TiO2-microcentrifugation columns 
and analyzed by HPLC-coupled ESI-Q-TOF-MS/MS (LC-MS/MS).  
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In total, we found 16 phosphorylated peptides as determined by detection of the 
neutral loss of 98 Da per phosphate group from the parent ion, which corresponds to 
phosphoric acid and occurs at phosphorylated serine or threonine residues but not 
tyrosine residues (data not shown). We were able to identify sequences of eleven 
phosphoserine (pS)- or phosphothreonine (pT)-peptides, out of which eight peptides 
were fragmented in the LC-MS/MS analysis of the tumor tissue and nine were 
fragmented in the analysis of the healthy tissue (Table 4.2). Two phoshopeptides were 
exclusively fragmented in the tumor tissue analysis, three exclusively in the healthy 
tissue analysis. Eight peptides matched the peptide motif of HLA-B*0702, and one 
peptide each was HLA-A*02, -A*24 and -B*35 restricted. Phosphorylation sites of nine 
peptides were known, two have been identified newly: pS1044 of the protein V-erb-b2 
erythroblastic leukemia viral oncogene homolog 3 (Erbb3, alternative name Her3) and 
pS139 of the protein Familiy with sequence similarity 128, member B (Fam128b). One 
peptide was a known HLA ligand: KPRpSPVVEL from the protein Adrenergic beta 
receptor kinase 1 (Adrbk1) (196).  
Presence of a peptide in one of the samples was further investigated by an LC-MS 
analysis (without fragmentation of peptides) performed from a mix of the two 
differentially labled peptide pools (Table 4.2). In this analysis, which allowed direct 
comparison of both samples, two peptides were detected as single peaks representing 
one peptide exclusively present in the tumor tissue (with an intensity ratio of 5.7 to 
background) and one peptide being present only in the healthy tissue (with an 
intensity ratio of 7.7 to background) (Table 4.2). All other peptides, which had been 
found fragmented only in the analysis of one of the samples, appeared as pairs (i.e., 
peaks with a 4 Da difference in the mass to charge ratio (m/z)) in the LC-MS run. 
Hence, out of eleven phosphopeptides one peptide was detected as tumor-restricted: 
RPRLQHSFpSF presented by HLA-B*35 and derived from the protein butyrate 
response factor 1 (pS203-Brf1195-204). Interestingly, the HLA-B*07 restricted 
phosphopeptide FPRRHpSVTL found in both the tumor and healthy tissue derives 
from the same protein (pS54-Brf149-57). The two MHC presented peptides contained two 
out of three known phosphorylations of Brf1 (291, 369, 370). Yet, phosphorylation of 
S54 had not been confirmed by MS so far. Brf1 is a zinc finger protein that – in the 
unphosphorylated state - regulates mRNA levels by targeting transcripts containing 
AREs (AU-rich elements) into the decay pathway (371).  
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Table 4.2 Phosphorylated HLA class I ligands identified from RCC tumor tissue and the corresponding healthy tissueb 
 
a Underlined residues indicate known phosphosites (www.phosohosite.org). 
b Isolation of peptides from tissue was done by Anneke Neumann (Department of Immunology, Institute of Cell Biology, University of Tübingen). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  LC-MS/MS LC-MS     
Peptide a HLA Tumor Healthy Tumor Healthy Gene GeneID Position Phosphosite 
RPRLQHSFpSF B*35 + - + - ZFP36L1 (BRF1) zinc finger protein 36, C3H type-like  677 195-204 (338) pS 203 
FPRRHpSVTL B*07 + + + + ZFP36L1 (BRF1) zinc finger protein 36, C3H type-like  677 49-57 (338) pS 54 
KAFpSPVRSV A*02 + + + + ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 3398 2-10 (134) pS 5 
RFKpTQPVTF A*24 + + + + LOC387763 hypothetical LOC387763 387763 365-373 (435) pT 368 
RPRSLpSSPTVTL B*07 + + + + NEDD4L  neural precursor cell expressed, developmentally down-regulated 4-like 23327 423-434 (955) pS 428 
SPFKRQLpSL B*07 + - + + NUMB  numb homolog (Drosophila) 8650 288-296 (651) pS 295 
MPRQPpSATRL B*07 + + + + FAM128B family with sequence similarity 128, member B 80097 134-143 (158) pS 139 
KPRpSPVVEL B*07 + + + + ADRBK1 (GRK2) adrenergic, beta, receptor kinase 1 156 667-675 (689) pS 670 
RPFpSPREAL B*07 - + + + LUZP1 leucine zipper protein 1 7798 742-750 (1076) pS 745 
RPQRApTSNVF B*07 - + + + MYL9 (MRLC1) myosin, light chain 9, regulatory 10398 14-23 (172) pT 19 
RPRGpSQSLL B*07 - + - + ERBB3 (HER3) v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 2065 1040-1048 (1342) pS 1044 
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4.1.3.3  Naturally presented MHC class II ligands contain phosphorylations 
Although we were able to isolate MHC class II presented peptides from the RCC tissue 
used for analysis of phosphopeptides presented by MHC class I, the amount of peptides 
isolated was seemingly too little to detect phosphopeptides after enrichment. 
Therefore, we analyzed MHC class II bound peptides extracted from two cell lines, a 
human EBV-transformed B-LCL (JY: HLA-DR4, -DR6) and a human melanoma cell 
line (MaMel-8a: HLA-DRB1*01), for presence of phosphopeptides.  
We detected 57 phosphopeptides in the LC-MS/MS analysis of JY, and 48 in the 
analysis of MaMel-8a (data not shown); identification of sequences was possible for 27 
and 20 phosphopeptides, respectively (Table 4.3, Table 4.4). As typical for MHC class 
II ligands, most peptides were found in differing length variants, i.e., peptides can be 
grouped to seven ligands discovered from JY and ten from MaMal-8a (denoted as such 
in the following); one ligand was found in both analyses. We found peptide variants 
containing one, two or three phosphorylations. In the majority of peptides serine 
residues were phosphorylated; only one ligand carried the phosphorylation at a 
threonine residue. Nine out of 16 ligands were derived from transmembrane proteins. 
The source proteins of the other seven ligands were known to be located either in the 
cytoplasm and/or the nucleus. In contrast to the phosphorylation sites of the identified 
MHC class I ligands described above, the phosphorylation sites of the MHC class II 
ligands were mostly unknown: we newly defined twelve phosphorylation sites, four of 
which were the first phosphorylation sites described for the respective source proteins 
at all (pS35-CD20, pS624- and pS629-Frizzled 6, and pS414-Actin-related protein 10 
homolog). Strikingly, the majority of the newly described phosphorylation sites were 
contained in transmembrane proteins (nine out of twelve), whereas most of the 
known phosphorylation sites were contained in soluble proteins (four out of seven).  
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Table 4.3 Phosphorylated HLA class II ligands presented by the EBV-transformed B-LCL JY 
Peptide a Gene GeneID Position Phosphosites Protein location/function (phosphosite location) 
    GpSpSLKILSKGKRGG CXCR4 chemokine (C-X-C motif) receptor 4 7852 323-336 (352) pS324, pS 325 plasmamembrane receptor (cytoplasmic) 
    GpSpSLKILSKGKRGGH   323-337 (352) pS324, pS 325  
    GpSpSLKILSKGKRGGHS   323-338 (352) pS324, pS 325  
    GpSpSLKILSKGKRGGHSpS   323-339 (352) pS324, pS 325, pS 339  
  RGpSpSLKILSKGKRGGHS   322-338 (352) pS324, pS 325  
SRGpSpSLKILSKGKRGGHS   321-338 (352) pS324, pS 325  
    GSpSLKILSKGKRGGHS   323-338 (352) pS 325  
  GPKPLFRRMpSSLVG MS4A1 (CD20) membrane-spanning 4-domains, subfamily A, member 1 931 26-39 (297) pS 35 plasmamembrane receptor (cytoplasmic) 
  GPKPLFRRMpSSLVGP   26-40 (297) pS 35  
  GPKPLFRRMpSSLVGPT   26-41 (297) pS 35  
  GPKPLFRRMpSSLVGPTQ   26-42 (297) pS 35  
SGPKPLFRRMpSSLVGPTQ   25-42 (297) pS 35  
    pSPTIEAQGTSPAHDN LRMP (JAW1) lymphoid-restricted membrane protein 4033 75-89 (499) pS 75 ER transmembrane (cytoplasmic) 
    pSPTIEAQGTSPAHDNI   75-90 (499) pS 75  
    pSPTIEAQGTSPAHDNIA   75-91 (499) pS 75  
  ApSPTIEAQGTSPAHD   74-88 (499) pS 75  
  ApSPTIEAQGTSPAHDN   74-89 (499) pS 75  
  ApSPTIEAQGTSPAHDNI   74-90 (499) pS 75  
  ApSPTIEAQGTSPAHDNIA   74-91 (499) pS 75  
SApSPTIEAQGTSPAHDN   73-89 (499) pS 75  
    KSVKALSSLHGDDQDpS IGF2R insulin-like growth factor 2 receptor 3482 2394-2409 (2491) pS 2409 lysosomal transmembrane receptor (cytoplasmic) 
TTKSVKALSSLHGDDQDpS   2392-2409 (2491) pS 2409  
pSKQDIRGTKTEQSTIG KIAA1109 84162 1682-1697 (5500) pS 1682 transmembrane 
      pSNVTASPTAPACPSDKPA TNIP1 TNFAIP3 interacting protein 1 10318 94-111 (636) pS 92 cytoplasm, nucleus 
    DpSNVTASPTAPACPSDKPA   93-111 (636) pS 92  
GKDpSNVTASPTAPACPSDKPA   91-111 (636) pS 92  
FDKHTLGDpSDNES FTH1 ferritin, heavy polypeptide 1 2495 171-183 (183) pS 179 cytoplasm 
 
a Underlined residues indicate known phosphosites (www.phosphosite.org).
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Table 4.4 Phosphorylated HLA class II ligands presented by the melanoma cell line MaMel-8a 
Peptide a Gene GeneID Position Phosphosites Protein location/function (phosphosite location) 
      ASISRLpSGEQVDG FZD6 frizzled homolog 6 (Drosophila) 8323 623-635 (706) pS 629 plasmamembrane receptor (cytoplasmic)  
      ASISRLpSGEQVDGK   623-636 (706) pS 629  
      ASISRLpSGEQVDGKG   623-637 (706) pS 629  
      ApSISRLpSGEQVDGKG   623-637 (706) pS 629, pS 624  
SPAASISRLpSGEQVDGKG   620-637 (706) pS 629  
SPAApSISRLSGEQVDGKG   620-637 (706) pS 624  
KYpSPGKLRGN MXRA7 matrix-remodelling associated 7 439921 142-151 (204) pS 144 transmembrane 
YDLMDNKDKGSpS FAM62A extended-synaptotagmin-1 23344 1093-1104 (1104) pS 1104 intracellular membranes (cytoplasmic) 
VSKVMIGpSPKKV TNS3 tensin 3 (tumor endothelial marker 6) 64759 1434-1445 (1445) pS 1441 putative transmembrane 
     VMIGpSPKKV   1437-1445 (1445) pS 1441  
FSDpSEEEGEGGRKNSSN HDAC1 histone deacetylase 1  3065 420-436 (482) pS 423 nucleus 
FSDpSEEEGEGGRKN   420-433 (482) pS 423  
YTLPRQATPGVPAQQpSPSM AOF2 (LSD1) amine oxidase (flavin containing) domain 2  23028 834-852 (852) pS 849 nucleus 
FDVGKTQPPLMKRAFpSTEK ACTR10 actin-related protein 10 homolog (S. cerevisiae)  55860 399-417 (417) pS 414 cytoplasm  
TPSQHSHSIQHpSPERSGSGSVGN BCLAF1 BCL2-associated transcription factor 1 9774 257-279 (920) pS 268 cytoplasm, nucleus 
        IRSRpTPSASNDDQQE SGTA small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha 6449 299-313 (313) pT 303 cytoplasm 
  RSQIRSRpTPSASNDDQQE   296-313 (313) pT 303  
LRSQIRSRpTPSASNDDQQE   295-313 (313) pT 303  
  FDKHTLGDpSDNES FTH1 ferritin, heavy polypeptide 1 2495 171-183 (183) pS 179 cytoplasm 
LFDKHTLGDpSDNES   170-183 (183) pS 179 
 
a Underlined residues indicate known phosphosites (www.phosphosite.org). 
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4.1.4 Discussion 
Altered cellular signaling is often associated with malignant transformation (136, 178, 
179). Since signaling pathways are regulated to a large part by phosphorylation, the 
phosphorylation status of several cellular proteins differs between normal and 
malignant cells (136, 179). In addition, increased turnover of individual proteins is also 
marked by an increase of phosphorylation, since phosphorylation may target a protein 
for ubiquitinylation and thus degradation by the proteasome (20). Phosphorylated 
MHC class I ligands, which are derived mainly from cytoplasmic proteins, have been 
shown to exist, and the phosphorylation has been demonstrated to be due to 
differential phosphorylation of the corresponding source protein (176). MHC ligands 
containing phosphorylations which are specifically relevant for the proliferation of 
tumor cells represent potential targets for T cell-based cancer immunotherapy. To 
identify such ligands, in former studies, the repertoires of phosphorylated MHC class I 
ligands presented by tumor cell lines were compared to the repertoire presented by an 
EBV-transformed B-LCL (176). However, tumor cell lines bear the risk of presenting 
MHC ligands which contain phosphorylations reflecting in vitro conditions. With 
regard to application in cancer immunotherapy, it is crucial to investigate which 
phosphopeptides are actually presented in vivo. Therefore, we advanced a 
phosphopeptide enrichment technique for identifying phosphorylated MHC class I 
ligands from a patient’s RCC tissue. In order to assess whether a phosphopeptide may 
be cancer-related, we equivalently analyzed the phosphorylated peptides presented by 
the corresponding healthy renal tissue. Unexpectedly, nine out of eleven 
phosphopeptides identified were presented both by the tumor and by the healthy 
tissue. This suggests that these ligands might rather be typical for kidney tissue than 
associated to malignant transformation. Alternatively, the healthy tissue might have 
been influenced by the same growth factors as the tumor tissue, since both tissues 
were derived from the same kidney. Only two peptides were specific for either tissue. 
One phosphorylated MHC ligand was exclusively found presented by the tumor tissue: 
a peptide derived from the protein butyrate response factor 1 (Brf1): pS203-Brf1195-204. 
Interestingly, another phosphorylated MHC ligand derived from Brf1 was found in 
both tissues, tumor and healthy: pS54-Brf149-57. We cannot exclude that the peptide 
pS203-Brf1195-204 was present below detection limit in the healthy tissue. Yet, according 
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to literature phosphorylation of pS203 and pS54 may be regulated by two distinct 
pathways: it has been shown that phosphorylation is carried out in vivo by PKB/Akt 
(pS203) (369) and in vitro by MK2 (both pS203 and pS54) (370). Unphosphorylated Brf1 
regulates mRNA levels by targeting transcripts containing AU-rich elements (AREs) 
into the decay pathway (291). AREs containing mRNAs include highly regulated 
mRNAs, in particular transcripts from genes expressed upon stimuli by growth factors, 
such as cell-cycle genes and oncogenes (372-376). It has been demonstrated that 
PKB/Akt mediated phosphorylation of S203 and S92 inhibits Brf1 from promoting its 
regulatory mRNA decay activity (369). MK2-mediated phosphorylation of S203, S92 and 
S54 inhibits mRNA decay activity as well (370). The fact that we found the MHC ligand 
containing pS203 exclusively in the tumor tissue points into the direction that PKB/Akt 
activity might be upregulated specifically in the tumor tissue, whereas MK2 activity 
seems to be equal in both tissues. PKB/Akt regulates many key effector molecules 
involved in cell survival (377) and its activity has been shown to be frequently 
increased in RCC (378). The kinase is regulated by the PI3K signaling pathway, a 
pathway suppressed by tumor suppressor protein PTEN, which is often mutated or 
deleted in tumors, including RCC (379-383). Increased mRNA stability has been 
implicated in malignancy (reviewed in (376, 384, 385)). Thus, we conclude that the 
Brf1-derived phosphopeptide pS203-Brf1195-204 might represent an MHC ligand 
reflecting a cellular phenomenon connected to tumor progression. This finding 
demonstrates that the identification of phosphorylated MHC class I ligands from 
tumor tissue compared to healthy tissue appears to be a valuable strategy to identify 
tumor-associated MHC ligands for immunotherapy. 
Surprisingly, we did not find any of the phosphorylated HLA-A*02 ligands, which 
were identified by Zarling et al. on three tumor cell lines (melanoma and ovarian 
carcinoma) but not on EBV-transformed B-LCL (176). A reason for the lack of overlap 
might be that we used a different phosphopeptide enrichment technique and 
chemically modified the peptides in a different manner before analysis. However, we 
found several of these phosphopeptides presented by an HLA-A*02 expressing RCC 
cell line (Table 4.5, peptides were modified chemically as well). This rather indicates 
that the peptides might have been below detection limit in the analysis of the RCC 
tissue. Yet, we detected the one HLA-A*02 ligand, which we identified from the renal 
tissue (pS5-ID22-10), also in the analysis of the RCC cell line with similar signal 
intensity. The most probable explanation for the lack of overlap is that we examined 
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primary tumor tissue instead of tumor cell lines. The repertoires of phosphorylated 
MHC ligands seem to differ less between tumor cell lines cultured in vitro than to 
tumor tissue in vivo. This observation emphasizes the need to analyze actual tumor 
tissue rather than tumor cell lines in order to define tumor-associated 
phosphopeptides for immunotherapy. 
 
Table 4.5 Phosphorylated HLA-A*02 ligands presented by the RCC cell line RCC68 
Peptidea Gene (GeneID) Position Phosphosite
VMIGpSPKKV TNS3 tensin 3 (64759) 1437-1445 (1445) pS 1441 
TLApSPSVFKST C13orf34 chromosome 13 ORF 34 (79866) 38-48 (559) pS 41 
AVVpSPPALHNA BRD4 bromodomain containing 4 (full length transcript variant) (23476) 855-865 (1362) pS 858 
RQIpSQDVKL AMPD2 adenosine monophosphate deaminase 2 (isoform L) (271) 165-173 (879) pS 168 
RLLpSPLSSA RAVER1 ribonucleoprotein, PTB-binding 1 (125950) 581-589 (756) pS 584 
RQDpSTPGKVFL  NR2C1 nuclear receptor subfamily 2, group C, member 1 (7181) 61-71 (467) pS 64 
RTFSPpTYGL DMN desmuslin (23336) 426-434 (1253) pT 31 
SMTRpSPPRV SFRS2B splicing factor, arginine/serine-rich 2B (10929) 248-256 (282) pS 52 
 
a Underlined residues indicate known phosphosites (www.phosphosite.org). 
 
The majority of phosphorylated MHC class I ligands identified were presented by 
HLA-B*07, while only one HLA ligand each was found HLA-A*02-, A*24- and B*35-
restricted (Table 4.2). This bias might be due to the fact that basic amino acids at the 
N-terminus (applicable for eight out of eleven phosphopeptides identified) seem to be 
favorable for the fragmentation and detection of phosphopeptides by ESI-MS and that 
N-terminal arginine or lysine residues are found more frequently among HLA-B*07 
ligands than among ligands of other HLA alleles (see peptide motifs at 
www.syfpeithi.de). This suggests that some combinations of HLA alleles might be 
more beneficial for the identification of tumor-associated phosphopeptides from a 
patient’s tumor tissue than others.  
Proteins which are normally not degraded by the MHC class I but the MHC class II 
antigen processing pathway are membrane proteins (386). This class of proteins 
includes plasmamembrane receptors which play a major role in cellular signaling and 
are frequently phosphorylated upon stimulation. Presented on the cell surface by 
MHC class II molecules, phosphorylated peptides derived from such receptors might 
be of similar relevance for cancer immunotherapy as MHC class I phosphopeptides,  
since anti-tumor immunity is dependent not only on CD8+ T cells but also on CD4+ T 
cells (362-367). Although MHC class II molecules are normally only expressed by cells 
of the immune system, tumors have been shown to express MHC class II molecules as 
well (171, 387). Former studies pointed into the direction that phosphorylated MHC 
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class II ligands do not exist (196). In this study, we could show the contrary. Using the 
TiO2-microcentrifugation columns, we enriched and identified MHC class II 
phosphopeptides from both an EBV-transformed B-LCL and a melanoma cell line.  In 
summary, we identified 47 peptides, which were partly length variants of the same 
core ligand and contained up to three phosphorylations, mostly of serine residues. 
Twelve out of 19 phosphorylation sites identified were unknown; of three proteins we 
discovered the first phosphorylation sites at all. As expected, the majority of ligands 
were derived from transmembrane proteins and most of the novel phosphorylation 
sites are contained in these ligands. On the other hand, most known phosphorylation 
sites were contained in soluble proteins. Thus, the analysis of phosphorylated MHC 
class II ligands represents a method to identify novel phosphorylation sites in 
particular of transmembrane proteins, which seem to be undiscovered to a higher 
extent than those of soluble proteins. 
Several of the MHC class II ligands identified were derived from receptors which play 
a significant role in cellular signaling: Chemokine receptor 4, CD20, and Insulin-like 
growth factor 2 receptor (B-LCL JY); Frizzled 6 (melanoma cell line MaMel-8a). 
Phosphorylations contained in these ligands were located at the cytoplasmic part of 
the receptors. Thus, a function of these phosphorylations in signaling is likely. The 
two novel phosphorylation sites found within the ligand derived from the receptor 
Frizzled 6 are particularly noteworthy; they are the first phosphorylation sites 
identified for this protein. Frizzled 6 is a member of the Frizzled familiy of 7-
transmembrane-domain-receptors, which bind secreted Wnt proteins (388, 389). The 
Wnt signaling pathways are involved in the regulation of tissue and cell polarity, 
embryonic development, and the regulation of proliferation (390). Inappropriate 
activation of the Wnt signal transduction pathway plays a role in a variety of human 
cancers. The tumor suppressor protein APC (Adenomatous polyposis coli), a negative 
regulator for Wnt signaling, has been shown to be inactivated in most colon cancers 
(391-393). The majority of Frizzled receptors are coupled to the β-catenin canonical 
signaling pathway, which leads to the activation of Dishevelled proteins (Dvl), 
inhibition of GSK-3 kinase, nuclear accumulation of β-catenin and activation of Wnt 
target genes (390); yet, transduction of signals by Frizzled receptors is largely 
unknown (394). In contrast, Frizzled 6 has been shown to abrogate Wnt signaling in a 
ligand-dependent manner by inhibiting the ability of β-catenin to activate 
transcription of Wnt target genes (395). Accordingly, Frizzled 6 has been suggested as 
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a tumor suppressor protein. Cytoplasmic C-terminal phosphorylation, as found in this 
study within the Frizzled 6-derived MHC class II ligand of a melanoma cell line might 
possibly inactivate the receptor and promote its internalization and degradation with 
the consequence of increased expression of β-catenin target genes. This hypothesis 
would be consistent with previous observations that Frizzleds transduce signals 
through G-proteins (396-398) and that phosphorylation of the C-terminus by G-
protein-coupled receptor-associated protein kinases (GRKs) is associated with 
attenuation of signaling, receptor internalization, and protein turnover (399). In any 
case, knowledge of the first two phosphorylation sites within the C-terminus of 
Frizzled 6 will likely advance investigation of the Wnt/Frizzled/β-catenin signaling 
pathways.  
Similarly, within the MHC class II ligands identified from a B-LCL, we have found 
two additional phosphorylation sites and confirmed the only one known of the 
chemokine (C-X-C motif) receptor 4 (CXCR4), a G-protein coupled recepetor, which 
is internalized upon ligand-dependent phosphorylation (400). All three 
phosphorylation sites identified in the MHC class II ligand (pS324, pS325, pS339) and 
phosphorylation of S338 have been proposed to be critical for internalization of the 
receptor (400). We demonstrate that internalized CXCR4 is indeed phosphorylated at 
S324, S325 and S339 as well as degraded and presented on MHC class II. S338 was not found 
phosphorylated within the MHC class II ligands and one ligand lacking 
phosphorylation of S324 was detected, suggesting that phosphorylation of these two 
serines might not be essential for internalization and degradation. CXCR4 is expressed 
in many cancers where it may regulate tumor cell growth and migration and therefore 
might be a target in cancer treatment (401, 402). CXCR4 has further been shown to act 
as (co-)receptor for the entry of some HIV strains and to promote Env-mediated fusion 
of the virus and thus has been proposed as target for antiviral drug development (403-
405).  
Also worth mentioning, we have found the first phosphorylation site within the 
receptor CD20, a B-cell antigen located in proximity to MHC class II molecules, 
against which therapeutical antibodies are directed in treatment of B-cell non-
Hodgkin’s lymphoma and autoimmune disorders (406-409). In summary, our results 
show that analysis of phosphorylated MHC class II ligands represents a convenient 
way to increase knowledge of natural phosphorylation sites within significant 
plasmamembrane receptors. 
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One crucial question remains to be answered in the next step: can all phosphorylated 
ligands be distinguished from their unphosphorylated counterparts by CD4+ T cells? 
Discrimination has been shown previously (368), however, it seems possible that 
recognition of the phosphorylation is dependent on its location within an MHC class 
II ligand: a phosphorylation in the central part of a peptide and thereby within the 
binding groove of the MHC class II molecule might be recognized rather than a 
phosphorylation located at the peptide’s termini. Among the peptides identified were 
both cases. The answer to this question will determine the relevance of individual 
phosphorylated MHC class II ligands for application in cancer immunotherapy. 
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5 Summary / Zusammenfassung 
 
Human leukocyte antigens (HLA) present protein-derived peptides to T lymphocytes. 
The knowledge of HLA ligands presented by certain types of cells (e.g., virus infected 
or cancer cells) allows for stating against which molecular compounds, so called 
epitopes, a T cell-based immune response may be directed. 
    This thesis concentrated on the selective indentification of viral and phosphorylated 
HLA ligands by HPLC-coupled mass spectrometry. Peptides of viral origin are 
presented on HLA class I by virus-infected cells to CD8+ cytotoxic T cells (CTL), 
which kill the infected cell upon recognition. Phosphorylated HLA class I ligands have 
raised hope to play a role in the immune response to cancer, since cellular signaling, 
which is often altered in malignant cells, includes phosphorylation of proteins. 
Identification of viral or phosphorylated HLA ligands is challenging due to their low 
frequency and potential low abundance compared to that of self-ligands and non-
phosphorylated peptides.  
     A novel approach using differential stable isotope labeling of HLA ligands purified 
from infected and mock-infected cells was applied to identify naturally processed viral 
HLA ligands. The virus analyzed was modified vaccinia virus Ankara (MVA), which is 
currently being tested as recombinant and smallpox vaccine. 15 viral peptides of 
which twelve were presented by HLA-A*0201 and three by HLA-B*0702 were found. 
Nine peptides have not been described as CTL epitopes so far. All HLA-A*0201 ligands 
were actual memory CTL epitopes in MVA vaccinees. Eight of these epitopes were 
novel. All ligands were expressed early during the viral life cycle, although late 
protein synthesis was not impaired. Importantly, early viral HLA ligands mediated 
protection against a lethal respiratory challenge in mice while late viral peptides 
previously described as CTL epitopes were inefficient. Thus, knowledge of the 
peptides which are actually presented by infected cells is crucial for optimizing the 
monitoring of protective immune responses and for the development of effective 
peptide-based vaccines.  
     In addition, this differential analyis revealed two human self-HLA ligands which 
were highly upregulated in the MVA-infected cells, suggesting either specifically 
induced synthesis and/or degradation of the source proteins upon infection. Both 
ligands were derived from cytoskeletal proteins. Unusually high presentation of self-
ligands in association with infection might potentially induce self-reactive T cells 
playing a role in autoimmune responses observed during vaccinia virus vaccination. 
     By developing TiO2-based microcentrifugation columns, the first phosphorylated 
HLA class I ligands presented by tumor tissue (renal cell carcinoma) were identified. 
By comparison to the ligands of healthy renal tissue one phosphorylated Brf1-derived 
HLA ligand was found as potentially tumor-associated. Moreover, the first natural 
phosphorylated HLA class II ligands were discovered. They revealed several novel 
phosphorylation sites of transmembrane receptors playing a significant role in 
malignant signaling, such as Frizzled 6, CXCR4 and CD20. 
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Zusammenfassung: 
Humane Leukocyten-Antigene (HLA) präsentieren aus Proteinen stammende Peptide 
den T-Lymphocyten. Die Kenntnis von HLA-Liganden, die von bestimmten Zelltypen 
(z.B. Virus-infizierten oder Krebszellen) präsentiert werden, ermöglicht es Aussagen 
zu treffen, gegen welche molekularen Komponenten, so genannte Epitope, eine T-
Zell-Antwort gerichtet sein kann.   
    Fokus dieser Arbeit war die gezielte Identifizierung von viralen und 
phosphorylierten HLA-Liganden mittels HPLC-gekoppelter Massenspektrometrie. 
Peptide viralen Ursprungs werden von HLA Klasse I auf virus-infizierten Zellen den 
CD8+ cytotoxischen T-Zellen (CTL) präsentiert, die die infizierte Zelle nach 
Erkennung abtöten. Bezüglich phosphorylierten HLA Klasse I-Liganden besteht die 
Hoffnung, dass sie in der Immunantwort gegen Krebs eine Rolle spielen, da die 
zelluläre Signalweiterleitung, die in malignen Zellen oft gestört ist, Phosphorylierung 
von Proteinen umfasst. Die Identifizierung von viralen oder phosphorylierten HLA-
Liganden ist dadurch erschwert, dass diese im Vergleich zu Liganden aus zelleigenen 
Proteinen und nicht-phosphorylierten Liganden in geringer Anzahl und 
möglicherweise auch Menge auftreten.  
    Zur Identifizierung von natürlich prozessierten viralen HLA-Liganden wurde ein 
neuer Ansatz verfolgt, der auf der differenziellen Markierung von HLA-Liganden aus 
infizierten und nicht-infizierten Zellen mit stabilen Isotopen beruht. Bei dem 
untersuchten Virus handelte es sich um das Modified Vaccinia Virus Ankara (MVA), 
das zurzeit als rekombinanter und Pocken-Impfstoff getestet wird. Es wurden 15 virale 
Peptide identifiziert, davon wurden zwölf auf HLA-A*0201 und drei auf HLA-B*0702 
präsentiert. Neun dieser Peptide wurden zuvor noch nicht als T-Zell-Epitope 
beschrieben. Alle HLA-A*0201-Liganden erwiesen sich tatsächlich als CTL-Epitope in 
MVA-Impflingen. Acht dieser Epitope waren neu. Alle Liganden stammten aus 
Proteinen, die früh im viralen Lebenszyklus gebildet werden, und dies obwohl die 
späte Proteinsynthese nicht gehemmt war. Eine wichtige Beobachtung war, dass 
Mäuse durch Impfung mit frühen viralen HLA-Liganden gegenüber einer letalen 
eingeatmeten Viruslast geschützt waren, während späte Peptide, die zuvor als CTL-
Epitope beschrieben worden waren, diesen Schutz nicht boten. Um den Verlauf von 
schützenden Immunantworten optimal zu überwachen und um effektive Peptid-
basierte Impfstoffe zu entwickeln, ist es also unverzichtbar, die Peptide, die tatsächlich 
von infizierten Zellen präsentiert werden, zu kennen.  
    Durch diese differenzielle Analyse wurden zusätzlich zwei humane HLA-Liganden 
gefunden, die auf den MVA-infizierten Zellen stark überpräsentiert waren, was darauf 
hinweist, dass die Proteine, aus denen diese HLA-Liganden stammten, durch die 
Infektion hervorgerufen verstärkt synthetisiert und/oder abgebaut wurden. Beide 
Liganden stammten aus Proteinen des Cytoskeletts. Ungewöhnlich starke Präsentation 
von Liganden körpereigener Proteine in Verbindung mit einer Infektion könnte 
selbst-reaktive T-Zellen aktivieren, die eine Rolle in den Autoimmunreaktionen 
spielen könnten, die bei Impfungen mit dem Vaccinia Virus aufgetreten sind.  
    Mittels selbst entwickelter TiO2-Mikrozentrifugationssäulchen gelang es, die ersten 
phosphorylierten HLA Klasse I-Liganden aus Tumorgewebe (des Nierenzellcarcinoms) 
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zu identifizieren. Durch den Vergleich mit Liganden, die aus gesundem Nierengewebe 
identifiziert wurden, wurde ein phosphorylierter HLA-Ligand aus dem Protein Brf1 
gefunden, der möglicherweise in Verbindung mit dem Tumorwachstum stehen 
könnte. Außerdem wurden die ersten endogenen phosphorylierten HLA Klasse II-
Liganden entdeckt. Sie enthielten einige bisher nicht bekannte Phosphorylierungs-
stellen von Transmembranrezeptoren, die eine bedeutende Rolle in der Signal-
transduktion von Krebszellen spielen, wie zum Beispiel Firzzled 6, CXCR4 und CD20. 
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